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1. List of abbreviations 
API - active pharmaceutical ingredient 
ATR - attenuated total reflectance 
CLP - clopidogrel bisulphate 
DSC - differential scanning calorimetry 
DTA - differential thermal analysis 
DVS - dynamic vapour sorption 
EC - Ethyl cellulose 
FT IR - Fourier transform infrared spectroscopy 
HPC - Hydroxypropyl cellulose 
HPMC - Hydroxypropyl methylcellulose 
ICH - International Conference on Harmonisation 
LOQ - Limit of Quantification 
MX - Meloxicam 
NIR - Near infrared 
NMR - Nuclear magnetic resonance 
PEG - polyethylene glycol 
PVA - polyvinyl alcohol 
PVP - polyvinylpyrrolidone 
SEM - scanning electron microscopy 
ss-NMR – solid state nuclear magnetic resonance 
TEM - transmission electron microscopy 
TG - thermo gravimetry 
Tg - glass transition temperature 
Tm - melting point 
XRD - X-ray diffraction 
XRPD - X-ray powder diffraction
 2. Introduction 
Investigation of the crystal structures of pharmaceutical materials is a continuously 
increasing interest. The variety of the order of molecules in the unit cell of an API can result 
differences in dissolution rate, wettability, solubility or bioavailability. Since it is essential to 
monitor these properties during development, methods for the investigation of crystal 
structure are increasingly in the focus. 
Technological methods to obtain a product with more suitable properties (i.e. faster 
dissolution and complete distribution) or to achieve better flow, particle size reduction may be 
needed. The methods that are available to reach these goals are operate with high kinetic 
energy, especially if the required particle size interval is at the nano range. This energy can be 
enough to transform the crystal structure of the material and corrupt its pharmacokinetic 
properties. 
A wide range of instruments are available to investigate even small changes in crystal 
structure of a material. The limits of quantification of these devices are sufficiently low to 
allow distinctions to be made between apparently identical materials. This has reached such a 
high level, that Walter McCrone stated that:  
 
“…the number of (polymorphic) forms known for a given compound is proportional to 
the time and money spent in research on that compound.” 
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3. Aims 
In present study, our primary aim was to investigate the changes in crystallinity of 
selected materials, which differ in many aspects, especially in glass-forming properties. To 
achieve this, we compiled the following steps: 
 
1. to establish the literature background of investigation methods which are suitable to 
follow changes in crystallinity of organic materials with small molecular weights. 
2. to find an easy and rapid method, that is able to predict the glass-forming properties of 
given materials. 
3. to select excipient pair, which are similar chemically, but differ in crystal structure; 
which are relatively inexpensive, widely used in pharmaceutics and have different glass-
forming properties. Mannitol and sorbitol turned out to possess these properties. 
4. to characterize the change in crystallinity of MX without any excipient and also with 
polymers (PEG, PVP) using different investigation methods. 
5. to characterize the amorphization tendency of CLP by co-grinding with an inorganic 
silicon dioxide (Aerosil 200). 
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3. Literature background 
3.1. The importance of the amorphous form in pharmaceuticals 
Amorphous or glassy materials are in the solid phase, but unlike crystalline ones they 
lack long-range order (Yu, 2001). This means that the orders of the molecules are similarly 
random to each other as in the liquid phase. They may have short-range order, though they 
can exhibit this over merely a few molecules (Hancock, et al. 1997). The absence of well-
defined molecular packing gives glassy materials different physical and physical-chemical 
properties, such as higher enthalpy and free energy, and a greater volume (Figure 1).  
 
Figure 1 Temperature parameters of crystalline and amorphous forms. Tg: glass transition temperature; 
Tm: melting point. (Kauzmann, 1948) 
Since amorphous materials do not possess a well-ordered crystal structure, their lattice 
energy is also at a minimum level. Consequently, they will not have a characteristic Tm, as 
crystalline materials do. They respond to heating from low temperature by softening at a 
specific point, which is called the glass transition temperature (Tg). Below Tg amorphous 
materials are generally brittle and rigid, while above it they are rubbery or viscous.  
Due to these circumstances, the amorphous form will always be thermodynamically 
unstable and will tend to recrystallize, as demonstrated many times (Fukuoka et al. 1986; 
Yoshioka et al. 1994; Hancock et al. 1995). They have a high capacity to absorb water, they 
are extremely hygroscopic, and they display considerable chemical reactivity (Pikal et al. 
1978). 
In pharmaceutics most often organic materials with relatively small molecular weight 
are used. These materials, investigated from a structural view, normally feature complex 
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molecular geometry, high conformational flexibility, and extensive hydrogen bonding. 
Therefor pharmaceutical solids have high tendency to present in amorphous form. Amorphous 
form can appear through the following ways:  
a) When the aim is to improve some disadvantageous properties of the drug, it can 
be prepared in an amorphous form. Through the destruction of the order of the 
molecules, the lattice energy, which is a thermodynamic barrier to dissolution, 
will remain at the minimum too. In that case the dissolution rate and water 
solubility can be enhanced (Hancock & Parks, 2000; Rodríguez-Spong et al., 
2004; Takeuchi et al., 2005; Zhang et al, 2004). 
b) When the formulation contains a partially amorphous form of the organic 
material at room or body temperature. This can occur when the substance is easy 
to amorphize or when one of the excipients of the formulation is able to bind the 
API molecularly (e. g. PVP, colloidal silicon dioxide). With these types of 
additives, the dosage form will be at least partially amorphous (Craig et al. 
1999). 
c) When the material is accidentally converted into an amorphous form by a 
pharmaceutical technique. The techniques, that are able to amorphize the 
material are those, which involve the use of the drug in the liquid phase (solvent 
techniques or hot-melt techniques) (Kumar et al. 2011; Carpentier et al. 2003; S. 
Qi et al. 2008) or are able to provide sufficiently high energy (e. g. milling) 
(Sharma et al. 2009).  
The pharmaceutical industry has high interest in case a), when an amorphous solid is 
made deliberately to avoid the disadvantageous properties of a given material. Three basic 
ways have been developed to amorphize the APIs: 
- Solvent methods: The API is dissolved in a good solvent, then it is evaporated 
as fast as possible. This can be done by heating, pressure reduction or 
evaporation. This is one of the simplest processes developed for amorphization, 
although it has its weaknesses: as the materials usually have low water 
solubility, large amounts of organic solvents are needed. Some of these organic 
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solvents tend to make inclusions, or leave traceable solvent residuals (Kim et al. 
2008; Takeuchi et al. 2005; Rossmann et al., 2012).  
- Hot-melt techniques: The material is heated above its Tm and then immediately 
cooled down, or a suitable excipient is melted and the API is dissolved in the 
melt. This method appears easy, but it has its limitations. Though most materials 
have relatively low melting points, this is still an energy-intensive process. 
Furthermore it can be highly challenging to move and treat the material in the 
liquid phase (Pokharkar et al. 2006; Saerens et al., 2012).  
- Milling techniques: The drug may be milled alone, or with an excipient in a co-
milling or co-grinding method. Due to the impact of the balls or rods of the mill, 
the crystal structure of the material is destroyed, while the friction is able to melt 
it locally, which causes a further crystallinity decrease (Watanabe et al. 2003; 
Mallick et al. 2008).  
Attention has nowadays started to turn to case c), when the amorphous form is not a 
particular aim, but is a result of one of the techniques used during the formulation. These 
techniques are widely used in pharmaceutical technology since; the currently discovered 
effective molecules are mostly poorly water soluble. To launch them in an appropriate 
formulation is the task of pharmaceutical technology.  
Popular methods such as the formulation of salts (Tarsa et al. 2010), complexes (Dai et 
al. 2013), or cyclodextrin-inclusions (Aigner et al., 2012) usually require solvent evaporation 
or crystallization from the melt, and there is therefore a high possibility of obtaining an 
amorphous final product. Freeze-drying methods are widely used to make parenteral dosage 
forms, but the amorphization of lyophilized product must be reconed with, since the solvent, 
which is generally water, evaporates rapidly (Kumar et al. 2011). 
Another way can that be chosen to improve the dissolution rate of a poorly water-
soluble drug: is to reduce the particle size to the micro- or the nano range (Ambrus et al. 2013; 
Chen et al. 2011). These processes demand high energy input, which again readily allows the 
material to be present in amorphous state: the impact of balls or rods, or the destructive effect 
of ultrasound or cavitation is capable of destroying the molecular structure of any material. 
Spray-drying can also be an effective method of adjusting the particle size to the required 
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range. Needless to say, the rapid solvent evaporation leads to a high chance of amorphization 
(Pomázi et al. 2011; Takeuchi et al. 2004). 
Tableting, a process initiating high pressure and friction can also be the source of 
accidental amorphization (Bozic et al. 2008). 
3.2. Prediction of amorphization  
In view of the circumstances detailed above the possibility of predicting of the 
amorphization or glass-forming properties of any given material is essential. From the aspect 
of whether a material is easy to amorphize or not two groups can be distinguised: poor and 
good glass-formers. Most authors calculate with the ratio of Tg and Tm. Kerč & Srčič, (1995) 
classified poor glass-formers as those with 0.7<
Tm
Tg ; while for good glass-formers is
7.0>
Tm
Tg . Although this is widely accepted, the ratio for poor glass-formers in other 
publications is: 5.1>
Tm
Tg ; while that for good glass-formers is: 5.1<
Tm
Tg (Craig et al., 1999, 
Hancock & Zografi, 1997.) 
Obviously the values of Tg and Tm must first be determined. For this, the most suitable 
method is DSC. Observations indicate that Tg is usually between 65% and 80% of Tm 
(expressed in K) (Yu, 2001). If the investigated sample is a multicomponent system 
containing several amorphous units, the Gordon-Taylor equation could give a sufficient 
approximation of the value of Tg (Gordon & Taylor, 1952). 
3.3. The factor of excipients in an amorphous system 
When the aim is the preparation of amorphous solid, suitable excipients can be 
extremely helpful. In fact their usage may even be essential to reach the required goal.  
When a solvent technique is planned the most challenging problem is to dissolve the 
drug in some cheap, non-toxic, and if possible inorganic solvent. To achieve this, a co-solvent 
excipient is often needed, which enhances the wetting or the solubility of the drug in the main 
solvent (Teagarden et al. 2002; Miller et al. 2012). Carrier excipients may also be needed, e. 
g. during a spray-drying process (Chauhan et al., 2005; Takeuchi et al., 2005). 
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Hot-melt technologies, can be performed in two ways: the API is melted alone above 
its Tm and then cooled down rapidly (Qi et al. 2008) or it is dissolved in a suitable melted 
excipient, which has an appropriate low Tm.  
The amorphization of materials by grinding has a high energy demand. This energy can 
be reduced by adding a suitable excipient and performing a co-grinding procedure (Choi et al. 
2009; Kürti et al. 2011; Merisko-Liversidge 2008). An appropriate additive also helps to 
prevent the aggregation of nanoparticles, lubricates the system, and increases the water 
solubility of the API.  
Since materials in the amorphous phase are less stable than crystalline substances and 
have a high tendency to return to a crystalline form, stabilization can be needed, so as to 
prevent the product from recrystallization during subsequent formulation, packaging, storage 
and usage. An ideal stabilization additive also prevents the amorphous material from 
undergoing chemical degradation. The stabilizing action of these crystallization inhibitors 
depends on different mechanisms: 
- Vitrification-based stabilizers immobilize and isolate substances in rigid glasses 
of inert stabilizer molecules. This reduces the potential of aggregation and 
diffusion of molecules. 
- Direct drug-excipient interactions (e. g. hydrogen-bonding) can maintain the 
material practically molecularly bonded to the stabilizer, thereby preventing it 
from undergoing recrystallization. 
- Molecular encapsulation can also be used for stabilization, as the API inside 
the “capsule” is practically amorphous. 
- Storage temperature: On the basis of previous studies (Hatley 1997; Hancock 
1997) Yu (2001) proposed the rule, that the storage temperature should be 
approximately 50 K below Tg. Tg can be set with the aid of suitable additives, 
since the binary mixture has a lower Tg. 
8 
 
Pharmaceutical excipients include several materials which meet the requirements, but 
most of them are polymers. The most widely used as grinding materials are the different types 
of PEG, PVP, PVA, cellulose ethers and esters (e.g. HPC, HPMC, EC). 
When certain excipients are used to formulate a partially amorphous form of the 
material, additives can facilitate the amorphization. The problem of undesirable 
amorphization chiefly appears in dosage forms where the API is in the solid phase. This can 
occur in solid, semi-solid, or liquid formulations too, such as powders, granules, tablets, 
suppositories, ointments or suspensions too.  
These products nearly always involve filler agents. Most commonly, starch, 
microcrystalline cellulose, sugar-alcohols or lactose is used. Numerous literature examples 
refer to the glass-forming properties of these additives (Bialleck. et al. 2011; Sato. et al. 2012; 
Reitz et al. 2013; Vollenbroek et al. 2010). 
Binders are indispensable in a well-formulated granule or tablet. They also may cause 
difficulties as they readily bind other materials, turning them into amorphous form. The 
widely used binders, such as different celluloses, acrylic acid copolymers, PVP are able to 
amorphize the API (Kotiyan et al. 2001; Watanabe et al. 2003; Mura et al. 2002). 
Similar characteristics may be displayed by disintegrant agents. They must have a high 
water absorption capacity to burst the particles of granules or tablets physically. Such 
properties are possessed by polymeric materials e. g. starches, crosspovidones or sodium 
hydrogen carbonate. These materials are also capable of decreasing the crystallinity of any 
active agent (Lin et al. 2012; Martini et al. 1991). 
To increase the solubility of the API solubility-enhancing agents may be used. They 
can operate with different mechanisms such as the inclusion formulation property of 
cyclodextrins (Al-Marzouqi et al. 2007; Sangwai & Vavia 2013), solubilizing with 
polysorbates (Zhang et al. 2012), or the ability of PEGs of making solid solutions 
(Papadimitriou et al. 2012; Yam et al. 2011). 
Colloidal silicon dioxide (Aerosil) is widely used as an adsorbent because of its large 
surface area, or as an antistatic additive, because of its ability to discharge the formulated 
system. It is well known that colloidal silicon dioxide is an agent, with a high ability to turn 
materials into amorphous form (Chauhan et al. 2005; Takeuchi et al. 2005).  
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Aerosil is also used as a glidant and lubricant. For this, magnesium stearate, talc, 
stearic acid and different hydrogenated vegetable oils are also used. These materials may 
further cause a crystallinity decrease of the active agent (Watanabe T. et al. 2002). 
Moisture retention additives such as glycerol or sorbitol, which can also be 
sweeteners, can reduce the crystallinity of the API (Tee S. K. et al. 2000).  
Further groups of additives include many other excipients, which can induce the 
amorphization of a drug, e. g. coating agents (different celluloses, acrylic acid copolymers) 
or viscosity increasing agents (different celluloses, gelatine, alginates) or ointments and 
suppository bases (vaselins, PEGs or fatty glycerides).  
4. Method applied for investigation of the amorphous form 
The methods for the investigation of amorphous materials are based on the various 
physical and physico-chemical properties: as they can differ in appearance, molecular 
structure, intra-molecular interactions and hygroscopicity, they can be investigated with a 
broad number of devices. Since the amorphous and crystalline forms are chemically 
equivalent, the amorphous form can only be measured in the solid state. Depending on the 
detection and quantification limit of the device two or more complementary methods are 
advised (Aaltonen et al., 2009). 
The choice of the most suitable and reliable investigation device and method is a real 
challenge for a pharmaceutical scientist. The requirements it has to meet are cited in the ICH 
(1996) Guidelines of Quality. During the validation of such a method, the following 
properties are monitored and validated: Accuracy, Precision, Repeatability, Intermediate 
Precision, Specificity, Detection Limit, Quantitation Limit, Linearity, and Range of the 
instrument. 
Those instruments and methods will next be demonstrated which are applied most 
frequently in the pharmaceutical industry to investigate the amorphous form, with special 
attention to those used during our investigations. 
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4.1. X-ray crystallography 
XRD methods are the most commonly used to investigate the crystallinity of any solid 
material (Uvarov & Popov 2008; Li, et al. 2000; Kim et al. 2008). The theory of XRD is that 
X-ray beams are diffracted at specific angles from the electron cloud of the molecules. The 3-
dimensional structure of the crystal can therefore be observed in a 2-dimensional 
diffractogram. The equation of diffraction was described by Henry and Lawrence Bragg: λ = 
2 d sin θ, where d is the spacing between diffracting planes, θ is the incident angle, n is any 
integer, and λ is the wavelength of the beam (Figure 2) (Jauncey 1924). The X-ray beam 
arriving from a certain angle is scattered by the molecules and produces secondary circular 
waves emanating from the electron cloud. A regular array of scatters produces a regular array 
of spherical waves, but these waves cancel one another out in most directions through 
destructive interference, they add constructively in a few specific directions. 
These intensifications and attenuations can be plotted in a 2-dimensional X-ray 
diffractogram, where the shot angle of the beam (2θ) is plotted on the x axis and the intensity 
of the reflected or transmitted beam on the y axis. 
By means of this phenomenon, single-crystals, powders or powder mixtures can be 
observed. As the amorphous form can only exist in a solid phase mass, XRPD devices can be 
used.  
The main task for operation with an XRPD device is the sample preparation: to avoid 
non-preferred orientation and to obtain a homogeneous powder sample, particle size setting is 
usually needed. Through this physical activation, although XRPD is a non-destructive 
method, the amorphous product can be destroyed by recrystallization (Moore et al. 2009).  
An XRPD measurement can yield quantitative and qualitative information (Tian et al. 
2007). To improve the applicability of the XRPD devices, they can be equipped with hot-
Figure 2 The Bragg's diffraction 
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humidity chamber, so that the crystallinity can be measured at different temperatures and 
humidity values (Guguta C. et al. 2008). 
4.2. Thermal analysis 
With thermal analytical instruments all the changes, which occur on temperature change 
can be measured. As the amorphous form exhibits different thermal behaviour as the 
crystalline form, these methods can be suitable to investigate and characterize the glassy form. 
The main analytical methods are: TG, DTA and DSC. 
TG involves a use of an instrument which records the mass change of a sample in 
response to temperature change (Wyttenbach et al. 2013). As it gives only partial information 
about the crystal structure of the material, it is often utilized as an additional analytical 
method during investigations of amorphous forms. 
DTA and DSC measure the heat flow of a sample in response to temperature change, 
but DTA is not capable of giving accurate calorimetric information and its usage has started to 
decline. DSC measures the amount of heat required to increase the temperature of a sample in 
proportion to a reference sample with a recording as a function of temperature. The measured 
signal stems from the difference in temperature of the sample and the reference. As the ending 
temperature is usually high enough to ignite the sample, a protective gas is used, which can be 
any noble gas (normally argon), or nitrogen. Sample preparation is important, as is the correct 
choice of sample holder: there are different holders on the market, which can protect the 
sample, or give a faster heat change, depending on what is needed.  
For the investigation of an amorphous material, DSC is the most common analytical 
method used (Jójárt-Laczkovich & Szabó-Révész, 2011; Qi et al., 2008; Sonje et al. 2011; 
Royall, 1999). 
4.3. Vibrational spectroscopy 
Vibrational spectroscopic devices operate in the infrared region of the electromagnetic 
spectrum. This part of the electromagnetic spectrum is divided into 3 sub-regions: the near-
infrared (approximately 14000-4000 cm−1); the mid-infrared (approximately 4000–400 cm−1); 
and the far-infrared (approximately 400-10 cm−1).  
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The theory of infrared spectroscopy is based on the fact that the frequency of 
electromagnetic radiation is the same range as the frequency of the vibrations of the bonds 
between the atoms of the molecules. Thus, the molecules being measured will absorb, reflect 
or transmit the infrared beam. The intensity of the absorbed, reflected or transmitted photons 
can be measured and this can give qualitative or quantitative information. The most current 
methods are the FT IR, Raman and NIR.  
The FT IR method measures the vibrational modes, which can change the dipole (they 
are IR-active modes). These are: symmetric and asymmetric stretching, scissoring, rocking, 
wagging and twisting. In practice this means that the CH2X2 groups, (where X can represent 
any other atom) can be investigated. Consequently in the case of amorphous systems, FT IR 
can provide only chemical information (Priemel, 2012; Ambike, et al. 2004). For the 
investigation of amorphous systems FT IR with an ATR accessory is the best choice, as it 
does not need difficult sample preparation (Schönbichler et al., 2013). 
Qualitative and quantitative information on amorphous systems can be obtained by a 
complementary method of FT IR: Raman spectroscopy (Hédoux et al., 2009). This is based 
on Raman scattering, when the light beam suffers inelastic scattering on the electron cloud of 
the molecule. In this case, the reflected beam contains photons with both higher and lower 
frequencies. In practice it is widely used, as the vibrational information it gives is specific for 
the chemical bonds and the symmetry of the molecules. 
NIR spectroscopy is widely used in pharmaceutics, because the near infrared beam 
penetrates much further into the sample than the mid-infrared beam and can provide valuable 
chemical information, especially about C-OH groups (which is suitable to characterize 
hydrogen bonding). This makes it a good analytical method for in-line use (Saerens et al., 
2012). 
4.4. Other methods 
Besides optical microscopy, other more advanced microscopy techniques are also 
suitable to investigate the appearance of amorphous form: SEM and TEM can provide a good 
visual view of the sample (Karavas E. et al. 2007). The SEM method produces images of a 
sample by scanning it with a focused beam of electrons; consequently it gives information 
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about the surface, while TEM visualizes the particle shape: it measures the beam of electrons 
transmitted through an ultra-thin specimen, interacting with the specimen as it passes through 
(Priemel et al., 2013; Shah et al., 2012). 
Some techniques take advantage of special properties of the amorphous material. One 
such method is DVS which measures the changes in mass at different relative humidity 
values. The theory behind this is that the amorphous material can absorb more water, than the 
crystalline material, so that even the crystallinity degree can be calculated after a calibration 
(Shah et al., 2006; Vollenbroek et al., 2010).  
NMR can also give valuable information about the crystallinity of a material, but only 
in the solid state: solid-state NMR (ss-NMR) permits the observation of specific quantum-
mechanical magnetic properties of the atomic nucleus. The asymmetric broadening of the 
NMR line observed in the amorphous state is due to an inhomogeneous distribution of 
isotropic chemical shifts, which can be assigned to static fluctuations of bond or torsion 
angles (Shah et al., 2006; Lefort et al., 2004). 
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5. Materials and Methods 
5.1. Model materials of the crystallinity decrease 
5.1.1. Finding the model materials 
To choose the most suitable model materials for our study 30 possible materials, 
commonly used in pharmaceutics were investigated. Melting points (Tm), glass transition (Tg) 
and their ratio were measured with DSC equipment. 5 mg (± 10%) of each pure crystalline 
form of the materials was measured into Al chambers. Heating was first applied up to slightly 
over the melting point. This determined the Tm. After the whole amount of the sample had 
melted it was cooled down to below the Tg as fast as the device allowed (approximately 45 
°C/min), measurement was then repeated. If the crystalline form of the material emerged, it 
was considered as poor glass-former. If the amorphous form appeared, the ratio Tg/Tm was 
calculated and the glass-forming properties were concluded on this basis. The results to be 
seen in Table 1. 
For further investigations, we chose materials from the groups of poor and good glass-
formers. Two similar sugar-alcohols with dissimilar glass-forming properties were also 
chosen. 
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Table 1 Measured Tg/Tm ratios of model materials and the glass-forming properties 
Material (Tm;°C) (Tg;°C) Tg/Tm (K/K) Amorphous 
Glass forming 
poroperties 
Tenoxicam 226 - - No poor 
Mannitol 166.9 - - No poor 
Niflumic-acid 205.4 - - No poor 
Teophylline 271.6 - - No poor 
Lidocaine 70.1 - - No poor 
Naproxen 156.4 - - No poor 
Sulfametoxazol 169.53 - - No poor 
Trimetoprime 200.64 - - No poor 
Econazol-nitrate 165.71 - - No poor 
Sertakonazol 160.3 - - No poor 
Etacrin-acid 124.7 - - Yes poor  
Meloxicam 264 63.5 0.63 Yes poor 
Ibuprofen 77.4 -42.5 0.66 Yes poor 
Diclofenac 177.0 34.24 0.68 Yes poor 
Carbamazepine 191.6 51 0.70 Yes good 
Piroxicam 203.1 58.1 0.70 Yes good 
Proranolol HCl 165.2 37.8 0.71 Yes good 
Lacidipine 184.8 54.4 0.71 Yes good 
Gemfibrozil 61.5 -29.2 0.73 Yes good 
Sulfadimidin 196.7 76.5 0.74 Yes good 
Sorbitol 91.4 0.77 0.75 Yes good 
Loratadine 137.6 40.4 0.76 Yes good 
Clopidogrel HSO4 181.2 88.9 0.80 Yes good 
Chlorhexidine 140.3 61.7 0.81 Yes good 
 
 
5.1.2. Mannitol and sorbitol 
We first investigated the crystallinity changes of β-D-mannitol ((2R,3R,4R,5R)-Hexan-
1,2,3,4,5,6-hexol) and D-sorbitol ((2S,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol). Both materials 
were purchased from Hungaropharma (Budapest, Hungary) and met the quality requirements 
of Ph.Eur.8 (Figure 3). 
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Both are widely used in pharmaceutics as sweeteners, bulking agents or moisture 
stabilizers (Kim et al., 1998; Maury et al., 2005). Both are stable and inert compounds, 
properties which make them a good choice as excipients during tableting, freeze-drying, 
capsulizing, granulating or grinding (Tee et al., 2000; Gombás et al., 2003). They are often 
used together as carrier additives usually in pulmonary delivery systems (Hamishehkar H. et 
al. 2010). Both can exist in many polymorphic, solvate, hydrate and amorphous forms 
(mannitol has 3 stable polymorphs and sorbitol has 5) (Cavatur et al., 2002; Nezzal et al., 
2009). 
 
Figure 3 Chemical structure of mannitol and sorbitol 
5.1.3. Meloxicam 
Pure crystalline MX (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-benzothiazine-
3-carboxamide-1,1-dioxide) was purchased from EGIS Ltd. Budapest, Hungary (Figure 4). 
MX is a non-steroidal anti-inflammatory drug that is mainly applied in therapy as an 
anti-inflammatory and strong analgetic agent (Hanft et al., 2001). MX is practically insoluble 
in water, while it displays a relatively high permeability through cell membranes. It was 
chosen as model compound because it is capable of hydrogen-bond to other materials. 
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Figure 4 Chemical structure of meloxicam 
5.1.4. Clopidogrel bisulphate 
Pure polymorphic form II CLP (methyl (+)-(S)-alpha-(2-chlorophenyl)-6,7-
dihydrothieno[3,2-c]pyridine-5(4H)-acetate sulphate) was obtained from EGIS Ltd., 
Budapest, Hungary (Figure 4).  
CLP is an oral antiplatelet drug, which is often used in the treatment of coronary artery 
disease, peripheral vascular disease and cerebrovascular disease. The amorphous and 
polymorphic forms of CLP has been prepared and described in the literature (Német et al., 
2009; Jójárt-Laczkovich & Szabó-Révész, 2010). 
 
Figure 5 Chemical structure of clopidogrel bisulphate 
5.1.5. Additives 
PVP C30 (with a molecular weight of 58,000), obtained from BASF (Ludwigshafen, 
Germany) and PEG 6,000 from Sigma-Aldrich Chemie GmbH, (München, Germany), were 
used as grinding excipients. Aerosil 200 (colloidal SiO2, with hydrophilic properties) was 
purchased from Nippon Aerosil Co., (Japan). 
The various PEGs are used in the pharmaceutical industry as binders, carriers, 
lubricants, etc., thanks to their advantageous properties: PEGs are completely biocompatible, 
they can exhibit a combination of hydrophilic and lipophilic properties and they are 
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commercially available in various molecular weights. As semicrystalline materials, they have 
melting points in the range from 3 to 68 °C, depending on the molecular weight (Yam et al., 
2011). Their importance in pharmaceutical research is increasing, in consequence of their 
ability to enhance the dissolution rate of numerous poorly water-soluble drugs (Leuner et al., 
2000). 
PVP is also produced in various molecular weights and particle sizes. These materials 
are mostly used as binders, matrix polymers, disintegrants, crystallization inhibitors and 
stabilizers. In the literature, PVP has often been used as an additive during co-grinding, 
serving as a carrier or to prevent aggregation (Martini et al., 1991). It has also been 
demonstrated that it can decrease the crystallinity of API during methods providing high 
energy (Mura et al., 2002).  
We earlier verified that PEG and PVP can be applied as suitable additives to decrease 
the energy requirements of grinding, to help reduce the particle size to the nano range, to 
prevent the aggregation of nanoparticles and to increase solubility (Kürti et al., 2011). 
5.2. Methods of sample preparation 
Physical mixtures of the crystalline sugar-alcohols (mannitol and sorbitol) and stabilizer 
polymer additives (PVP C30 and PEG 6,000) were prepared and charged into a hard 
polyamide mortar. Equal amounts of agate balls were also placed into the chamber. The mass 
ratio of the mixtures was in all cases 1:1. The grinding processes were carried out with a 
Fritsch - Pulverisette® planetary ball mill. Mixtures were ground at 120 min on 400 rpm. 
Samples were withdrawn for investigation after 20, 40, 60, 80, 100 and 120 min. 
Physical mixtures of MX, as API, and the grinding (stabilizer) polymer (PEG 6 000 or  
PVP C30) were prepared and charged into the stainless steel jar of a planetary ball mill 
containing 10 stainless steel balls (Retsch PM 100, Retsch GmbH & Co., Haan, Germany). 
The mass ratios were based on previous work (Kürti et al., 2011), so as to give nanoparticles 
(200-600 nm). For the PVPs, the drug-excipient mass ratio was 1:1, while for the PEGs it was 
1:2. Mixtures were ground for 140 min, samples being withdrawn for investigation after 20, 
40, 60, 80, 100, 120 and 140 min. During the grinding process, the temperature of the mortar 
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was measured with an infrared thermometer immediately before sample withdrawal. The 
temperature of the mortar was not higher than 56 °C throughout milling. 
The co-grinding of the mixture of CLP and Aerosil 200 was performed in a planetary 
ball mill (Retsch PM 100, Retsch GmbH & Co., Germany). The mass ratio of CLP and 
Aerosil 200 was 7:3. This ratio was based on a previous work by our team (Jójárt-Laczkovich  
& Szabó-Révész, 2011). The maximum grinding time was 240 min. Samples were withdrawn 
for investigation after 15, 30, 45, 60, 90, 120, 150, 180 and 240 min. 
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5.3. Methods of investigation 
5.3.1. X-ray powder diffraction (XRPD) 
XRPD analysis was performed with Bruker D4 and Bruker D8 Advance diffractometer 
(Bruker AXS GmbH, Karlsruhe, Germany) systems with Cu K λI radiation (λ = 1.5406 Å). 
The samples were scanned at 40 kV and 40 mA from 3° to 40° 2θ, at a scanning speed of 
0.05°s-1 and a step size of 0.010°. The crystallinity of the mannitol and sorbitol samples was 
determined as ratio of the areas beneath characteristic and separate peaks of physical mixtures 
and samples and was expressed as percentage (%). These peaks are specific for each material; 
none of them is a double peak, or covered by the peak of the semicrystalline PEG. The 
crystallinity of the MX and CLP samples were determined via the total area beneath the curve 
between 12° and 30° 2θ. All manipulations of diffractograms and the calculation of area 
under curves were performed with DIFFRACTplus EVA software. 
In the case of MX samples, we used an internal standard method to avoid the problems 
caused by the particle size reduction and randomly oriented particles. This technique is widely 
applied for quantitative XRPD.  As internal standard, we mixed 20% (w/w) of pure crystalline 
NaCl into the binary mixtures. Before its application, the particle size of the NaCl was set into 
the similar range as that of the MX (2643.6 ± 2629.1 nm). After Kα2-stripping, background 
removal and smoothing of the areas under the peaks, the area under the peak of MX was 
proportioned to the area under the peak of NaCl (31°-32.5° 2θ). 
5.3.2. Differential scanning calorimetry (DSC) 
DSC data were recorded with a Netzsch STA-409 (Selb, Germany) and a Mettler-
Toledo DSC 821e instruments with intercoolers. 4.5-5.5 mg samples were crimped in 
aluminium pans with two holes and were examined in temperature interval 25-200 °C under 
an argon gas flow at 100-150 ml min-1, at heating rates of 10 and 20 °C min-1. 
5.3.3. Thermogravimetry (TG) 
TG curves were obtained with a TGA/DSC1 (Mettler-Toledo, Switzerland). 4.5-5.5 mg 
of the samples were crimped in aluminium pans with two holes and were examined in the 
temperature interval 25-200 °C. Heating rate was 20 °C min-1. 
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5.3.4. Fourier transform infrared (FT IR) spectroscopy 
FT IR spectra were recorded with a Bio-Rad Digilab Division FTS-65A/896 FT IR 
spectrometer (Bio-Rad Digilab Division FTS-65A/869, Philadelphia, USA) between 4000 and 
400 cm−1, at an optical resolution of 4 cm−1; operating conditions: Harrick’s Meridian 
SplitPea single reflection, diamond, ATR accessory. Thermo Scientific GRAMS/AI Suite 
software (Thermo Fisher Sciencific Inc., Waltham, USA) was used for the spectral analysis. 
For FT IR determinations, the ATR method was chosen, because with this there is no 
need for sample preparation, such as particle size reduction or KBr tableting, which would 
expose the samples to further physical stress. 
5.3.5. Scanning electron microscopy (SEM) 
The morphology of the MX particles was examined by SEM (Hitachi S4700, Hitachi 
Scientific Ltd., Tokyo, Japan). A sputter coating apparatus (Bio-Rad SC 502, VG Microtech, 
Uckfield, UK) was applied to induce electric conductivity on the surface of the samples. The 
air pressure was 1.3-13.0 mPa. Briefly, the samples were sputter-coated with gold–palladium 
under an argon atmosphere, using a gold sputter module in a high-vacuum evaporator and the 
samples were examined at 10 kV and 10 μA. MX particle diameter distributions were 
obtained by analysing several SEM images with the ImageJ software environment. 
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6. Results 
6.1. Investigation of sugar-alcohols 
6.1.1. Determination of crystallinity of mannitol  
The DSC measurements indicated that the ratio Tg/Tm (K/K) for pure β-D-mannitol (Tg: 
285.75 K Tm: 440.05 K) is lower than 0.7, suggesting that this compound has only a low 
tendency to exist in amorphous form. β-D-mannitol has linear molecules and an orthorhombic 
crystal structure, which is preferable for the development of strong long-range order among 
the molecules. 
Thermoanalytical techniques such as DSC or DTA are suitable methods for 
investigation of the crystallinity of samples. From the areas under the peaks of melting of the 
samples can be concluded. DSC measurements demonstrated that the raw mannitol did not 
suffer any loss in crystallinity during the grinding process, and it exhibited a similar 
characteristic melting peak at the same temperature (440.05 K ± 3.1 K), with identical 
enthalpy (ΔH= 41.02 Jg-1 ± 1.13 Jg-1) as for raw mannitol itself. The mannitol samples made 
with polymer additives behaved similarly to pure mannitol: the amorphous PVP has no peak 
in the DSC curve, while the semi-crystalline PEG had a broad melting peak at around 338 K; 
the mannitol in the mixtures displayed identical melting action to that without polymers. 
Specific peaks relating to the melting point of mannitol appeared in the curves with slightly 
varying enthalpy (ΔH= 22.04 J g-1 ± 0.83 J g-1) indicating that the mannitol maintained its 
well-defined long-range order in the crystal structure. 
XRPD measurements can also be used to investigate the crystal structure of ingredients. 
LOQ of XRPD methods is low enough for them to be used for quantitative measurements. In 
case of clopidogrel bisulfate polymorphs and olanzapine polymorphs the LOQ were 1.0–1.5 
% (w/w) and 1.22% (w/w) respectively. The areas under diffraction peaks are related to the 
crystallinity and the decrease in crystallinity can be calculated from the changes in the 
independent characteristic peaks.  
XRPD measurements were performed on each of the raw materials and samples. 
Amorphous PVP exhibited a halo with no specific peaks in the diffractogram, while PEG, as a 
semicrystalline polymer gave a few broad peaks in the investigated range (Figure 6). Pure 
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mannitol displayed peaks characteristic of the β-D form (sharp peaks at the following 2θ 
values: 10.441°, 14.572°, 18.722°, 21.019°, 23.374°, 28.282°, 29.444°, 31.728°, 38.645° and 
44.052°). After 120 min of grinding, the same peaks were found in the curve. No shifts were 
observed, no peaks disappeared and no new peaks appeared. The areas under peaks at 9.5-11° 
2θ; 13.7-15.5° 2θ and 17.7-19.9 ° 2θ were calculated for each sample that was withdrawn. 
This revealed that, although some peaks decreased to an irrelevant extent, no fundamental 
change in crystallinity occurred during grinding (Figure 7). 
 
Figure 6 X-ray diffractograms of pure PVP C30, PEG 6000, and mannitol; and mannitol samples ground 
for 120 min with PVP C30 and PEG 6000. 
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Figure 7 Crystallinity change of mannitol and mannitol ground with polymer additives (PVP and PEG) as 
a function of the milling time. 
Same grinding and investigation method was applied in the presence of the polymer 
additives. The samples containing PEG gave the peaks characteristic of mannitol and the 
broad peak relating to PEG at around 22-24° 2θ. Crystallinity determination (based on the 
same peaks as utilized in the case of raw mannitol) proved that minor amorphization took 
place after 40 min of milling. No polymorph transition was observed: no peaks underwent a 
shift or disappeared and no new peaks were detected. Slightly different behaviour was 
observed for the samples containing PVP. The peaks were specific for mannitol, but the areas 
under the curves decreased with increasing grinding duration. The degree of this decrease 
exceeded the LOQ and could not be interpreted in terms of a decrease in particle size. The 
change in crystallinity during the milling did not exceed 70%. After 40 min of grinding an 
apparent equilibrium set between the crystalline and amorphous phases.  
6.1.2. Crystallinity determination of sorbitol 
The ratio Tg/Tm (Tg and Tm in K) measured for D-sorbitol was 0.75 (Tg: 273.92 K Tm: 
364.55 K), which predicted this material is a good glass-former.  
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The DSC measurements showed that the sorbitol used was a mixture of the epsilon (Tm: 
364.55 K) and gamma (372.05 K) polymorphs. During the grinding process the proportions of 
the polymorphs changed. The pure material contained a predominance of the epsilon form. 
The milling led to a decrease in the amount of the epsilon form, while the amount of the 
gamma polymorph slightly increased (Figure 8). This means that the mechanical energy broke 
down the crystal structure of the crystalline epsilon sorbitol. Some of the amorphous material 
recrystallized due to the mechanical impact. 
 
Figure 8 DSC curves of pure sorbitol grinding, and sorbitol ground with PVP C30 
A similar phenomenon was observed in the DSC curves of sorbitol co-ground with 
PVP. The melting point of the sorbitol was lowered by the polymer excipient. Both 
polymorphs gave characteristic DSC curve. Similarly as when no additive was present, the 
epsilon polymorph amount decreased during the milling. In this case, the content of gamma 
polymorph also decreased, as demonstrated by the decrease of the area under the curve. The 
bulk part of the system lost its well-defined long-range order of the crystal structure.  
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The DSC investigation of sorbitol samples containing PEG did not show any significant 
change in crystallinity. The melting point of the semicrystalline polymer and the melting of 
sorbitol were to be seen in the curves. The areas under the melting peak of sorbitol varied 
only slightly during the milling (ΔH= 25.04 J g-1 ± 1.25 J g-1), within the error of the 
measurement. No amorphization or polymorphic alteration was noted during the milling of 
these two materials. 
To investigate the change in crystallinity of the co-ground sorbitol and to calculate the 
extent of amorphization, XRPD method was also carried out on the samples (Figure 9).  
 
Figure 9 X-ray diffractograms of pure PVP C30, PEG 6000, and sorbitol; and sorbitol samples ground for 
120 min with PVP C30 and PEG 6000. 
The peaks of X-ray diffractograms of pure sorbitol were mostly characteristic of the 
epsilon form, though the peaks of the gamma form were also present. The determination of 
the polymorphs was based on the calculated X-ray powder diffractograms obtained from the 
Cambridge Crystallographic Data Centre (CCDC).  During the milling process the areas under 
the peaks relating to the epsilon form noticeably decreased with milling time. In parallel the 
peaks of the gamma polymorph became slightly larger at a similar rate. This phenomenon 
which affected slightly more than 20% of the ground sorbitol could occur in two ways: 
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mechanical energy converted some of the material into the amorphous phase and the gamma 
form recrystallized from this; or the epsilon form was transformed directly to the gamma 
form. 
A similar polymorph transition took place during the grinding of sorbitol with PVP: 
peaks relating to both polymorph forms were found in the diffractogram of the physical 
mixture. During the milling process, the areas under the peaks characteristic of the epsilon 
form decreased markedly (Figure 10).  
 
Figure 10 X-ray diffractograms of sorbitol samples ground with PVP (withdrawn every 20 min). 
From the areas under the peaks of the epsilon form at 9.5-11° 2θ, 23.15-24.53° 2θ and 
28.2-29.6° 2θ, the degree of reduction in crystallinity was measured (Figure 11). During the 
first 40 min, the system lost about 50% of its well-defined crystal structure. After 40 min 
there was an apparent lag phase. At the end of the milling, slightly more than 30% of the 
sorbitol remained in the epsilon polymorph form. Most of the remaining 70% had lost its 
well-defined order of molecular packing and a minor part had been transformed into the 
gamma polymorph (Figure 12).  
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Figure 11 Crystallinity change of sorbitol and sorbitol ground with polymer additives as a function of 
milling time. 
 
Figure 12 Polymorphic transition of sorbitol during milling with PVP excipient. While the amount of the 
epsilon form decreases with the milling time, the amount of the gamma form increased. Diffractograms of 
epsilon and gamma forms were acquired from the Cambridge Crystallographic Data Centre 
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Only the peak at 11.5-12.1° 2θ is clearly related to the gamma form. All the other peaks 
were characteristic either of epsilon form or of both polymorphs. This gamma sorbitol peak 
was used to evaluate the polymorphic transition. Figure 13 illustrates the decrease in the 
epsilon form and the increase in the gamma form with the increasing milling time. The figure 
has two “y” axes scaled differently to demonstrate the similar courses of the changes in 
proportions of the two polymorphs. There was a strong decrease in epsilon form initially, 
which was accompanied by a comparable rapid increase in the gamma form. After an 
apparent lag phase between 40 and 80 min both changes (increase in the gamma and decrease 
in the epsilon) continued similarly. This polymorph alteration was confirmed by the changes 
in the other peaks. Whereas the peaks clearly relating to the epsilon form (for example those 
at 23.15-24.53° 2θ and 28.2-29.6° 2θ) decreased continuously with increasing grinding time, 
the common peaks (at 18.1-19.1° 2θ) diminished only slightly. All the changes observed are 
indicative of a constant crystallinity decrease as the milling time becomes longer, some of the 
sorbitol recrystallizing and changing into the gamma polymorphic form during the process. 
 
Figure 13 Crystallinity change of different sorbitol polymorphs. The left “y” axis is for the epsilon form, 
the right one is for the gamma form. The diagram shows the similar course of the decrease of the epsilon 
and the increase of the gamma form. 
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The samples containing PEG displayed different behaviour during mechanical 
activation. The degree of crystallinity changed by around 100% during the overall procedure. 
The sorbitol did not suffer any loss in crystal structure. As the sorbitol itself did lose its 
crystallinity noticeably in the absence of excipient, it can be concluded, that PEG stabilized 
the crystal structure of this sugar alcohol and helped it maintain its crystallinity. No 
polymorphic transformation was detected in the X-ray pattern. 
6.2. Investigation of crystallinity changes of MX 
MX was selected as model API because it has only a low tendency to occur in 
amorphous phase: Tg/Tm (K/K) is 0.63. The polymers were PVP and PEG. We set out to 
quantify the decrease in crystallinity in time and to detect any bonding formed between the 
MX and the polymers. 
6.2.1. X-ray diffraction 
Figures 14 shows the diffractograms of the samples prepared. In each graph, the 
characteristic peaks of MX can be observed. As PEG is semi-crystalline, it gives a large peak, 
with a considerable full width at half-maximum, while PVP is fully amorphous, so it does not 
yield any signal in the diffractograms. At 31.6° 2θ, the specific peak relating to NaCl appears. 
Figure 14a (PEG 6 000) demonstrates that no amorphization occurred during the co-grinding 
process: the areas under the peaks did not decrease radically. The samples prepared with the 
PVPs behaved differently: the areas under the peaks continuously decreased as the grinding 
time was lengthened (Figure 14b (PVP C30)). Although the drugs were not converted 
completely into the amorphous form, because the diffractograms exhibited small peaks in the 
amorphous halo, the change in crystallinity was drastic. During the co-grinding process, no 
other polymorphic form of MX appeared: no shift in the peaks and no new peaks were 
observed in the pattern. 
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Figure 14 XRPD diffractograms of MX mixed with PEG 6000 (a) and PVP C30 (b). 
To quantify the changes in time, the areas underneath the diffractograms were 
determined between 12° and 30° 2θ after Kα2-stripping, background removal and curve 
smoothing. The areas under the peaks relating to MX were divided by the areas under the 
peaks of NaCl. These values are illustrated in Figure 15, which shows the crystallinity 
changes based on the areas under the peaks. The samples made with PEG did not undergo any 
amorphization. The long-range order of molecular packing remained. The diversity of the 
values may be caused by the variation in particle size, and the orientation of the larger 
particles. Samples involving the use of PVP as grinding material lost their well-defined 
molecular conformation. The areas under the peaks decreased on increase of the grinding 
time. For PVP C30 12.23% of the MX remained in crystalline form at the end of the grinding 
process. 
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Figure 15 Crystallinity changes of the samples 
6.2.2. FT-IR spectroscopy 
To determine whether any decomposition occurred during the grinding process and to 
search for any possible bonding between the API and the polymers, FT-IR spectroscopy was 
carried out. This proved that no disintegration took place in any of the samples. The 
characteristic bands of MX were seen in all of the curves.  
No measurable changes were observed in the case of the products made with the PEGs. 
No shifts, no changes in band shape and no new bands were detected in the curves. This 
means that bonds between the materials were not created by grinding. Changes in the 
intensities of the peaks can be explained by the decreasing particle size of the products. 
The samples made with the PVP polymers exhibited several changes in the spectra 
during the grinding process (Figure 16), most significantly in the interval 3725-2600 cm-1. At 
3400-3500 cm-1, the intensity of the associated νOH mode increased with increasing grinding 
time. A similar increase was observed in the range of CH and NH valence vibrations, between 
3000 and 2800 cm-1. The separation of the two ranges is impracticable. 
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Figure 16  FI IR spectra of samples made with PVP C30. The arrows show increasing intensity at 3400-
3500 cm-1 and between 3000 and 2800 cm-1. 
The most significant changes for both excipients are related to the secondary amide 
group of MX. Increases in intensity can be observed at around 1620 cm-1 (νCONH) and 
between 1550 cm-1 and 1530 cm-1 (νNH). Further, the intensity relating to a hybrid stretching 
mode at around 1440 cm-1 is increased and a shoulder grows around 1390 cm-1 (Figure 17). 
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Figure 17 FI-IR spectras of the samples made with PVP C30. The arrows indicate changes related to 
secondary amide groups. Increasing intensities can be observed around 1620 cm-1 (νCONH) and between 
1550 cm-1 and 1530 cm-1 (νNH). 
All these alterations point to the presence of weak bonding between the carboxyl group 
of MX and the polymers, which is able to help the molecules to separate from each other and 
keep them in this (not well-defined) conformation. 
6.2.3. SEM 
Differences between the abilities of the polymers to decrease the crystallinity of MX 
can also be seen in the SEM photomicrographs. Figure 18 presents SEM pictures of physical 
mixtures and samples (ground for 140 min) made with PEG 6000 and PVP C30. PEG has 
relatively low melting points, which were exceeded during the co-grinding process (the 
temperature of the mortar was not higher than 55 °C). The polymers are locally melted by the 
impact and friction of the balls in the mortar. Reduced-sized MX particles can be observed in 
the melt of the polymer. These particles are in the nano range. 
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Figure 18 SEM photomicrographs of samples made with PEG 6000 (A: physical mixture, B: sample 
ground for 140 min) and PVP C30 (C: physical mixture, D: sample ground for 140 min) 
PVPs are amorphous polymers, and did not melt during the milling process. The 
temperature was locally higher than the Tg of the excipients, so the polymers softened and 
coated the amorphized MX. These MX particles more or less preserved their contour while 
they were decreased to the nano level. 
To identify the habit of the MX particles formed by the co-grinding with the polymers, 
the water-soluble excipients were extracted from the system by washing-out with cold 
distilled water, and the material was centrifuged three times. By this method, the water-
insoluble MX [the solubility of MX is 4.4 ± 0.7 μg mL-1 (Ambrus et al., 2009)] can be 
observed individually. The SEM images of the samples made with PEG (Figure 19A) 
revealed well-formed crystalline MX particles with sharp edges. The shape and position of the 
particles indicate recrystallization. The MX molecules could dissolve in the melted PEG 
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polymer, but immediately following the decrease of temperature, the MX precipitated out 
from the dispersion, forming crystalline particles. The samples made with the PVPs did not 
give sharp lines, but formed a shapeless amorphous mass (Figure 19B). 
 
Figure 19 MX particles, water-soluble polymer additives: PEG 6000 A; and PVP C30 B removed. 
6.3. Investigation of crystallinity change of CLP 
CLP was chosen as a model API, as it has a relatively high melting point, and did not 
melt in the milling chamber and it has a really high tendency to exist in amorphous form. Its 
Tg/Tm (K/K) ratio is 0.80. Aerosil 200 was used as carrier because of its amorphous properties, 
with neither any thermal sign, nor any peak in the XRPD diffractograms and its excellent 
properties as a crystallization inhibitor was cited (Chauhan et al., 2005; Watanabe et al., 
2001).  
6.3.1. DSC determination  
As thermal analysis techniques are widely used in the characterization of the amorphous 
form, the intact CLP, Aerosil 200 and the prepared samples were investigated by DSC. The 
curve of the raw CLP gave a characteristic sharp peak at 181.20 °C, corresponding to the 
melting point of the material. No other changes were observed on the curve, which means that 
the CLP contained no moisture or any residual solvent. The Aerosil 200 (as an amorphous 
additive) did not exhibit any thermal signal so it was practically amorphous and contained no 
moisture or any r residual est solvent either.  
The curves of the samples indicated the endothermic peak of the melting point of CLP 
in each case, except that at 240 min (Figure 20). The area of the peak decreased with 
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increasing grinding time until it practically disappeared after 240 min of grinding. The peak of 
the physical mixture was similar to the peak of the raw CLP, but with a smaller area. This 
indicates the decreasing crystallinity of the CLP, which was finally converted into the 
amorphous phase. The peaks are shifted slightly to lower temperatures during the grinding 
while a peak was observed at 80 °C after 120 min of grinding. 
 
Figure 20 DSC determination of samples. The endothermic peak of CLP appears in each curve, and the 
areas under the peaks decreased with the grinding time.  
It was impossible to determine the accurate area under each curves because of the 
imprecise pre- and post-baseline fittings of the melting peaks. The DSC method was not 
applicable for further semiquantitative determination. 
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6.3.2. X-ray diffraction 
XRPD is an appropriate method with which to determine the crystallinity of materials. 
The X-ray pattern of the raw CLP exhibits characteristic high-intensity diffraction peaks, 
which demonstrates the crystalline nature of the unprocessed API. Comparison of the results 
on the CLP used and the data recieved from the Cambridge Crystallographic Data Centre 
(CCDC ID: AI631510) proved, that our API was in polymorphic form II. The pattern of the 
Aerosil 200 does not show any peaks in the measured interval, which means that the excipient 
was practically amorphous. 
The typical peaks of the CLP emerged clearly in the diffractograms of the ground 
products (Figure 21). The intensities of these peaks were lower than those of the peaks for the 
raw API, corresponding to the concentrations of the materials in the samples.  The amorphous 
Aerosil 200 did not exhibit any further reflection. The intensities of these peaks decreased 
with increasing grinding time and practically disappeared after co-grinding for 240 min. The 
diffractogram of the last sample displayed the amorphous halo. During the co-grinding 
process, no other polymorphic form of the CLP appeared, no shifting of the peaks occurred, 
and no any new peaks were observed in the pattern. 
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Figure 21 XRPD diffractograms of samples. The characteristic peaks of CLP decrease with the increasing 
grinding time. The last sample (240 min) shows no peaks, so it is practically amorphous. 
Quantification of the crystallinity decrease is illustrated in Figure 22 which shows that 
of the crystallinity decreased sigmoidally with increase of the grinding time. The rise in the 
fitted trendline relates to the rate coefficient of formation of the amorphous product (the 
regression line equation is y = -0.0233x + 1.619 R2 = 0.9935). 
 
Figure 22 Crystallinity changes during grinding. First function shows the area under the curves 
decreasing with increasing grinding time; the second function is the linearization of the first. 
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This phenomenon revealed that the crystallinity of the products started to decrease 
slowly. After a certain time had elapsed, the decrease became faster, and at the end of the 
procedure the curve of the amorphization flattened. This phenomenon can be caused by in-
process secondary bonding formation between the API and the excipient, because the 
formation of the bond is an energy-intensive process. 
6.3.3. TG and hot-humidity stage XRPD 
The curves of the samples ground for more than 120 min demonstrated an endothermic 
peak at 80 °C. The area under this peak increased and sharpened with increasing grinding 
time. To identify the source of the peaks, the last sample (ground for 240 min) was 
investigated by TG and hot-humidity stage XRPD. 
The TG curve revealed, that the product was thermodynamically stable and a mass 
decrease of only 3,33% was detected up to the melting point of the CLP (Figure 23). At 80 
°C, the determination did not show a salient mass decrease, which means that the peak 
observed in the DSC pattern did not involve dissolution or solvent evaporation. Neither was 
any major decrease observed at 100 °C, which means that the sample was sufficiently dry. 
 
Figure 23 DSC and TG determination of sample ground for 240 min. No major mass decrease is detected 
at 80 °C, or at 100 °C. 
The last sample (ground for 240 min) was determined by XRPD, using the hot-humidity 
chamber at room temperature (25 °C), at the temperature of the peak (80 °C) and at a 
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temperature higher than the peak (95 °C). The diffractograms showed an amorphous halo in 
all three cases, so this peak did not relate to any change in crystallinity (Figure 24). 
 
Figure 24 Hot-XRPD diffractograms of samples ground for 240 min at 25°C, 80 °C or 95°C. Each 
diffractogram shows the amorphous halo. No changes in the crystallinity occured at these temperatures. 
The outlined phenomenon could be emerging secondary bonding between the API and 
the additive. The endothermic peak detected at 80 °C indicated the spliting of the bond. At 
higher temperature the CLP-Aerosil 200 complex broke down, giving a solid dispersion of the 
two independent materials. 
6.3.4. FT-IR spectroscopy 
 FT IR spectroscopy is a suitable method for the investigation of interactions between 
pharmaceutical materials and polymers. For FT IR determination the ATR method was 
chosen, because sample preparation, such as particle size reduction or KBr tableting, which 
would expose the samples to further physical stress, is unnecessary.  
FT IR determination showed that the grinding process caused several small changes in 
the spectra of the samples. One of the most spectacular changes was seen at 1752 cm-1, the 
region of the νC=O valence vibration of CLP. These peaks of the samples ground for more 
than 120 min expanded, shifted to lower wavenumbers, and slightly increased in intensity 
with increase of the grinding time (Figure 25).  
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Figure 25 FT-IR investigation of samples ground for 15 min or 240 min. The area under the peak at 1750 
cm-1 increased, and the peak shifted to lower wavenumbers. 
Another change was observed at 865 cm-1 where a band with high intensity started to 
decrease after 120 min of grinding, while a double peak at 858 cm-1 and 838 cm-1 fused into 
one peak with a higher intensity (Figure 26). These changes proportionally followed the 
changes at 1752 cm-1. The same phenomenon was observed between 1200 cm-1 and 1135 cm-
1: the peak at 1188 cm-1 decrease, while the peak at 1150 cm-1 slightly increased parallel after 
120 min of co-grinding. 
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Figure 26 The bands of Aerosil 200, CLP and 9 samples ground for from 15 min to 240 min. The area 
under the peak at 865 cm-1 decreased after 120 min of grinding, while the double peak at 858 cm-1 and 838 
cm-1 fuse into one peak with a higher intensity. 
The described changes can refer to the following processes: the CLP first temporarily 
melts forming a molecularly disperse system. After 120 min of grinding, a weak secondary 
bond appears between CLP and the silanol groups of the CLP. This bond is strong enough to 
keep the CLP in amorphous phase. The work of our team (Jójárt-Laczkovich & Szabó-
Révész,  2011), demonstrated that this secondary bond is a hydrogen-bond. 
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7. Summary, novelty and practical relevance 
1. Our first aim, to establish the literature background of investigation methods which are 
suitable to follow changes in crystallinity of organic materials with small molecule weights 
was accomplished: all of the widely used investigation methods were learnt and practiced. 
Those that were most suitable for our aims were chosen and used. 
2. An easy and rapid method, which is able to predict the glass-forming properties of 
given materials were applied: DSC method was carried out, with only a small amount of 
material and two heatings were needed to determine the glass-forming properties of each 
material. It was therefore quite simple to choose between the possible substances: two sugar-
alcohols, which are widely used in pharmaceutics, were selected: although they are 
chemically equivalent, they have different tendencies to exist in amorphous form. Interesting 
APIs were investigated: MX, although considered poor glass-former readily occurs in 
amorphous form, and CLP with its relatively high Tg/Tm ratio needed a long-term grinding 
with Aerosil to amorphize completely. The method used, which was suitable to decrease the 
degree of crystallinity of the chosen materials was relatively cheap. Its most important 
advantage was it repeatability and feasibility. 
3. First, two chemically equivalent sugar-alcohols (mannitol and sorbitol) as model 
materials were subjected to milling both alone and in the presence of polymer excipients 
(PVP C30 and PEG 6000) to accentuate the differences in behavior of analogous materials. 
As a poor glass-former, mannitol did not exhibit any decrease in crystallinity when it was 
milled alone or together with PEG. In the presence of PVP, the crystal structure of mannitol 
was slightly lost. When ground alone or together with PVP, sorbitol suffered amorphization 
and it underwent polymorph transformation when co-ground: the initial, mostly epsilon form 
was transformed continuously into the gamma form, while parallel lost more than 70% of its 
crystallinity. PEG preserved the well-ordered molecular packing of sorbitol and stabilized the 
crystal structure so that the sorbitol could not amorphize. It can be concluded that these sugar 
alcohols, which have the same chemical structure, demonstrated different rates of crystallinity 
loss. 
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4. A similar effect of polymers was proved by the grinding of MX: the work 
demonstrated that the polymers used to reduce the grinding energy during co-grinding to 
nanoparticles can decrease the crystallinity of MX. These polymers have different abilities to 
convert the drug into amorphous form. XRPD measurements confirmed that the PEG did not 
have a significant effect on the crystallinity of MX, while the PVP decreased it drastically. 
Weak secondary bonding between MX and the PVPs was found by FT IR. The SEM images 
confirmed the major particle size decrease and the differences in crystal behaviour of the 
samples made with the different polymers. 
5. Finally, raw, crystalline CLP was amorphized by co-grinding. It was found that the 
crystallinity decreased sigmoidally with increasing co-grinding time. XRPD and DSC 
examinations confirmed that the product had become totally amorphous after a relatively long 
time, 240 min of grinding. No polymorphic conversion was observed in the samples. TG 
proved that no major mass reduction occurred during the procedure. FT IR changes indicated 
the formation of a secondary bond between CLP and Aerosil 200, which is able to keep the 
drug in the amorphous phase. 
Finally it can be concluded, that so similar molecules as two chemically equivalent 
sugar-alcohols can behave completely different on effect of grinding. The study also revealed 
the possibility of polymorph transition, which can lead to issues in physical appearance, 
dissolution or stability.  
It was proven, that organic APIs, which amorphization inclination were predicted as 
different, can react similarly to a high energy intake: two material with dissimilar tendency to 
present in amorphous form exhibited comparable reaction to the co-grinding process. 
Important properties of excipients used as co-grinder additives were revealed too. Some 
of the materials can support amorphization by decreasing the energy devoted to grinding or 
stabilizing the molded amorphous dispersion. Meanwhile some of them can prevent the API 
from crystallinity loss by coating the particles and protect their structure from breaking down. 
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Bevezetés
Az amorf fázis, a szilárd fázis egyik alfázisa a 
kristályos alfázis mellett  [1]. Az amorf kifejezés 
alaktalan, formátlan, rendezetlen állapotot jelent. 
Ez utal arra, hogy egy amorf anyag kristályrácsá-
ban csak rövid távú rendezett ség alakul ki. Az 
ipar számos területén alkalmaznak különböző 
amorf anyagokat: az üveggyártásban, ahol a szilí-
cium-dioxid, mint kis molekulájú szervetlen anyag 
kerül felhasználásra, a műanyagiparban, ahol 
makromolekulás szerves anyagokat használnak, 
például a polietilént, illetve a gyógyszergyártás-
ban, ahol főleg kis molekulatömegű szerves anya-
gokat formulálnak.  
Célkitűzés
Munkánk során célunk volt átt ekintést adni az 
amorf formáról gyógyszer-technológiai szempont-
ból, illetve kristályos anyagok amorfi zálódását 
vizsgálni, egy egyszerűen és gyorsan elvégezhető 
gyorsteszt segítségével, amely alkalmas az amorf 
forma keletkezését szimulálni. Meghatároztuk az 
anyagok olvadáspontját (Tm), üvegesedési hőmér-
sékletét (Tg), valamint a kett ő arányából következ-
tetést vontunk le azok amorfi zálhatóságra. Továb-
bi célunk volt annak az ellenőrzése, hogy az iro-
dalmi közlésnek megfelelően a Tg valóban a Tm 2/3-
a illetve 4/5-e közé várható-e [1].
Az amorf forma jellemzése
Az amorf (üveges) forma jelenléte és vizsgálata a 
gyógyszeriparban fokozott , hiszen az amorf fázis 
viselkedése merőben eltér a kristályos anyagétól, 
tulajdonságai lehetnek hátrányosak, de előnyösek 
is. Az amorf anyag szabadenergiája, entalpiája, 
Summary
M á r t h a ,  C s . ,  J ó j á r t - L a c z k o v i c h  O . ,  S z a -
b ó - R é v é s z  P .: Amorphous form in pharmaceutical 
technological research
Detecting and analysing of the amorphous phase are increas-
ingly important in pharmaceutical technology. The amorphous 
or glassy state has a several advantages and disadvantages. The 
amorphous form can be applied in deliberate amorphization, 
when active pharmaceutical ingredient (API) is formulated in 
glassy state, or this form can appear accidentally during formu-
lation or storage. The aim of this study was to characterize glass-
forming properties of 13 diﬀ erent materials. Diﬀ erential Scan-
ning Calorimetry (DSC) was used as an analytical technique and 
Tg and Tm values were determined. The equation of Tg/Tm (K/K) 
was applied to determine the glass-forming tendencies. We made 
2 groups of investigated substances. The fi rst group was that we 
could not amorphized: tenoxicam, mannitol, nifl umic acid, theo-
phyllin and lidocain. The second group contains materials, which 
could be prepared in glassy form. This group can be divided into 
2 sub-groups: poor-glass formers and good-glass formers. Poor-
glass formers are following: meloxicam, ibuprofen and piroxi-
cam. Good-glass formers are lacidipine, gemfi brosil, sorbitol, lo-
ratadine, chlorhexidine and clopidogrel hydrogensulfate.
Keywords: amorphous, amorphization, accidentally amorfi -
zation, glass transition, DSC.
Összefoglalás
Az amorf forma kimutatása, vizsgálata és a különböző anya-
gok amorfi zálhatósági tulajdonságainak meghatározása egy-
re inkább előtérbe kerül a gyógyszertechnológiában. Az amorf 
fázis számos előnyös és hátrányos tulajdonsággal rendelke-
zik a kristályos fázishoz képest. Előnyös tulajdonságai miatt  
amorfi zálhatjuk közvetlenül a hatóanyagokat, vagy keletkezhet 
véletlenszerűen is különböző behatások miatt . Munkánk során 
13 ható- illetve segédanyag amorfi zálhatóságát vizsgáltuk egy 
termoanalitikai gyorstesztt el, amelyhez DSC készüléket hasz-
náltunk. Meghatároztuk az egyes anyagok olvadáspontját (Tm) 
és üvegesedési hőmérsékletét (Tg). A Tg/Tm (K/K) arány segít-
ségével meghatároztuk az anyagok amorfi zálhatóságát. A ka-
pott  eredmények alapján két csoportba soroltuk az anyagokat: 
az első csoport anyagait nem tudtuk amorfi zálni. Ezek voltak: 
a tenoxikám, a mannit, a nifl uminsav, a teofi llin és a lidokain. 
A második csoport anyagait üveges állapotba tudtuk vinni. 
Ezt a csoportot két alcsoportra osztott uk: az első alcsoportba 
a rosszul amorfi zálható anyagok tartoznak, amelyek a követ-
kezőek: ibuprofén, meloxikám és piroxikám. A második alcso-
port anyagai jól amorfi zálhatóak. Ezek a következők: lacidipin, 
gemfi brozil, szorbit, loratadin, klórhexidin, és a klopidogrel 
hidrogén-szulfát.
Kulcsszavak: amorf, amorfi zálás, véletlenszerű amorfi zá-
lódás, üvegesedési hőmérséklet, DSC.
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entrópiája és térfogata is nagyobb, mint a kristá-
lyosé. A hőmérséklet emelésével viszont szabad-
energiája csökken, entalpiája, entrópiája és térfo-
gata növekszik (1. ábra). Az amorf anyag általá-
ban higroszkóposabb és nagyobb oldódási sebes-
séggel rendelkezik, mint a kristályos, hiszen nem 
rendelkezik szabályos kristályráccsal, így rács-
energiával sem, amely az oldódás termodinami-
kai gátja. Az anyag üveges állapotában nem ren-
delkezik olvadáspontt al (Tm), viszont jellemző rá 
az ún. üvegesedési hőmérséklet (Tg). Az amorf fá-
zisra jellemző érték továbbá a Kauzmann hőmér-
séklet (TK), amelyen az amorf és a kristályos anyag 
entrópiája megegyezik. E hőmérséklet alatt  az 
amorf anyag stabilabbnak tekinthető a kristályos-
nál (Kauzmann paradox) [2].
A Tg alatt  az anyag rideg, törékeny, nehezen ala-
kítható, majd a hőmérséklet emelése és a Tg átlépé-
sét követően fokozatosan lágyul, és válik rugalm as-
sá. Ezért fontos tudni, hogy adott  anyag Tg értéke 
szobahőmérséklet alatt  vagy felett  található-e. Ta-
pasztalatok szerint a Tg az olvadáspont 2/3-a, 4/5-e 
között  várható Kelvinben számolva. A Tg és Tm ará-
nyából következtethetünk az adott  anyag amor-
fi zálhatósági tulajdonságaira: ha a Tg/Tm aránya na-
gyobb, mint 0,7 akkor az anyag jól amorfi zálható. 
Ha ez az arány kisebb, akkor a kristályos szerkezet 
letörése után a rendezetlen (amorf) forma szinte 
azonnal visszakristályosodik, tehát az anyag rosz-
szul amorfi zálható [1]. A hatóanyagok általában kis 
molekulájú szerves anyagok, amelyek a magas 
szerkezeti fl exibilitásuk miatt , sok esetben sorolha-
tóak a jól amorfi zálható csoportba.
Az amorf forma keletkezése
A gyógyszertechnológiai műveletek során két eset-
ben számolhatunk az amorf forma jelenlétével: a 
formulálandó kristályos 
anyagot közvetlenül amorf álla-
potba hozzuk. Ebben az esetben 
amorf hatóanyag áll rendelke-
zésre a gyógyszerforma kiala-
kításához. A másik esetben 
viszont a hatóanyag valamely 
gyártásközi művelet, esetleg a 
tárolás során, részben vagy 
akár egészében véletlenszerűen 
amor fi zálódik. 
A kristályos anyag amor-
fi zálására hagyományosan 
három különböző eljárást al-
kalmazunk:
− Oldószeres eljárás, amely során feloldjuk az anya-
got annak jó oldószerében, majd gyorsan eltá-
volítjuk azt, így a molekuláknak nincs elég ide-
jük, hogy szabályos kristályrácsba rendeződje-
nek, tehát mindez rendezetlen, amorf formát 
eredményez [3]. Az oldószer eltávolítása történ-
het hőmérsékletemeléssel, nyomáscsökkentés-
sel, porlasztással [5], fagyasztva szárítással [10], 
vagy szuperkritikus technológiával [6]. 
− Olvadék technológia (Hot-melt technology): amely-
nek egyik módja, hogy az anyagot az olvadás-
pontja felé hevítjük, majd hirtelen visszahűtjük 
[7], vagy egy megfelelő segédanyagot olvasz-
tunk meg, és az olvadékban diszpergáljuk a ha-
tóanyagot.
− Őrléssel, amelynek során a hatóanyagot magá-
ban, vagy segédanyaggal őrölhetjük különböző 
malmokban szobahőmérsékleten, vagy akár 
hűtve [8]. Az őrlés során fellépő mechanikai 
erők, a nyomás és a súrlódás miatt  keletkező hő 
okozta helyi olvadások amorfi zálhatják az 
anyagot [11–13].
Az amorf forma véletlenszerű keletkezését szá-
mos technológiai folyamat eredményezheti. Az ol-
dószer eltávolítás számos technológiai folyamat ré-
sze és sok esetben eredményezhet amorf terméket. 
A napjainkban egyre gyakrabban alkalmazott  ol-
vadék technológiák is képesek az anyagot amor-
fi zálni. Az olvadás során felbomlott  kristályrács 
egyes esetekben nem nyeri vissza a rendezett ségét 
a hűtést követően, amely így amorf formát ered-
ményez [9]. Ugyancsak amorf terméket kapha-
tunk, ha egy segédanyagot, pl. fi lmképzőt (PEG) 
megolvasztunk, és az olvadékban a hatóanyag fel-
oldódik [11]. Gyakran amorfi zálódik a termék 
szemcseméret csökkentés közben is. Őrléses eljárás 
során golyósmalomban vagy hengermalomban 
végzett  rövid ideig tartó őrlés is képes lehet rész-
1. ábra: Az amorf és a kristályos forma összehasonlítása szabadenergiájuk, entalpiájuk, 
entrópiájuk és térfogatuk hőmérséklet-függésében. Tg: üvegesedési hőmérséklet, Tm: 
olvadáspont, TK: Kauzmann hőmérséklet [2].
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ben, vagy egészében amorf formát létrehozni [11, 
13], de olyan eszközök, amelyek kisebb szemcse-
méret elérésére alkalmasak, mint például a nagy 
nyomású homogenizátor [14] vagy a kolloid ma-
lom [15], nagyobb valószínűséggel amorfi zálják a 
terméket. Leggyakrabban a préseléses eljárások, a 
tablett ázás és száraz granulálás (brikett ezés, 
kompak tálás), okoznak problémát: a művelet alatt  
fellépő nagy nyomás, és a súrlódás miatt i hő okoz-
ta helyi olvadások amorfi zálhatják a ható- vagy se-
gédanyagokat [17].
Az amorf forma vizsgálata
Az előzőekből következik, hogy számos esetben 
szükség lehet olyan vizsgálatokra, amelyekkel iga-
zolható a hatóanyag kristályos voltának teljes, 
vagy részleges hiánya, és a megjelenő amorf fázis 
kvantitatív meghatározása. Az amorf fázis detek-
tálása, és további vizsgálata szerkezetéből adódó-
an számos problémát vet fel:
1. Mivel termodinamikailag instabil rendszerek, 
mindig számolnunk kell visszakristályosodás-
sal a vizsgálat egésze során. Már a minta vétele 
során alkalmazott  fi zikai behatás, az eltérő hő-
mérséklet, páratartalom vagy légnyomás is 
okozhat olyan változást, ami hamis eredményt 
adhat.
2. Sok esetben a terméknek csak egy része amorf, 
és a maradék kristályos rész sem feltétlenül csak 
egyféle polimorf módosulatot tartalmaz. Előfor-
dulhat még, hogy a termékben az előállítás so-
rán keletkezett  instabil amorf rész elbomlása so-
rán keletkező bomlástermék is kimutatható.
3. Problémás lehet még a termékben lévő különbö-
ző komponensek egymás mellett  történő kimu-
tatása.
Az amorf fázis kimutatására leggyakrabban a 
diﬀ erenciális pásztázó kalorimetriát (DSC) alkal-
mazzák. A készülé k entalpiaváltozást detektál a 
hőmérséklet függvényében. A Tm endoterm csúcs-
ként jelenik meg a diﬀ raktrogramon, amelynek 
görbe alatt i területe arányos a mért anyag mennyi-
ségével. A 100%-ban amorf anyag diﬀ raktog ram-
ján nem láthatunk endoterm csúcsot. Ebből követ-
kezik, hogy a csak részben amorfi zálódott  anyag 
Tm-nél jelentkező csúcs görbe alatt i területe ará-
nyos a kristályos frakció mennyiségével. A készü-
lék képes az üveges átmenet detektálására is, egy 
endoterm alapvonal eltolódás (ún. endoterm lép-
cső) formájában. Ezen tartomány infl exiós pontját 
tekinthetjük a Tg-nek. Ha ezt a lépcsőt egy másik 
entalpiaváltozással járó történés elfedné, a jelensé-
gek szétválasztására használhatjuk a modulált fű-
tésű diﬀ erenciális pásztázó kalorimetriát 
(MTDSC). A készülék képes elkülöníteni a reverzi-
bilis változásokat az irreverzibilisektől. Az üvege-
sedési hőmérséklet, mint reverzibilis változás így 
elkülöníthető például az oldószer-vesztéstől, mint 
irreverzibilis változástól. Gondot okozhat még, ha 
kis mennyiségű amorf anyagot tartalmaz a kristá-
lyos minta. Ennek detektálására alkalmazhatunk 
gyors fűtésű diﬀ erenciális pásztázó kalorimetriát 
(Hyper-DSC) [18]. A DSC módszer alkalmas kris-
tályossági fok, illetve kristályosodási kinetika 
meghatározására is, hiszen a kristályos fázis olva-
dásakor jelentkező endoterm csúcs görbe alatt i te-
rülete egyenesen arányos a kristályos rész meny-
nyiségével. 
Használatos még az amorf fázis kimutatására a 
porröntgen diﬀ rakció (XRPD) is. Az atomi rácstá-
volságok nagyságrendjébe eső monokromatikus 
röntgensugár, az anyag periodikusan ismétlődő 
építőelemeinek elektronfelhőjéről szóródik. A su-
garak különböző szögek alatt  mérhető interferen-
ciája (kölcsönös erősítése, illetve gyengítése) infor-
mációt ad az anyag szerkezetéről.  Amorf minta 
esetén eltűnnek a kristályos formára jellemző jel-
legzetes csúcsok, a görbe úgymond kisimul [19]. A 
röntgendiﬀ rakció ugyancsak alkalmas kristályos-
sági fok, illetve kristályosodási kinetika meghatá-
rozására, hiszen a különböző szögek alatt  mért be-
ütések száma att ól függ, hogy mennyi kristályos 
anyagon haladt keresztül a röntgensugár. 
Kristályossági fok, illetve kristályosodási kineti-
ka meghatározására alkalmazhatjuk még a dina-
mikus gőzszorpciós (DVS) készüléket is. A méré-
sek alapját az adja, hogy az anyag amorf állapot-
ban higroszkóposabb, mint a kristályos [20]. Hát-
ránya, hogy a kristályos formában is erősen higro-
szkópos anyagok amorf formája nem, vagy csak 
nehezen detektálható.
Használatos még az amorf forma vizsgálatára a 
Raman-, a Furier transzformációs infravörös- (FT-
IR), a közeli infravörös- (NIR), a diﬀ úz refl exiós 
Furier transzformációs infravörös- (DRIFT), és a 
molekula spektroszkópia; a szilárd fázisú NMR 
(ssNMR), a termogravimetria (TG), a derivatív 
termogravimetria (DTG), a dielektromos analízis 
(DEA), a denzitometria, és a viszkozimetria [1]. 
A vizsgáló módszereink mindegyikére meg kell 
adnunk egy ún. legkisebb detektálható (DL: 
Detection Limit) és legkisebb mérhető mennyisé-
get (QL: Quantitation Limit) százalékban. Mindkét 
adat kiszámolására többféle lehetőség adott , ame-
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lyeket az ICH (International Conference on 
Harmonisation) iránymutatása határoz meg (Q2). 
Amorf tartalom meghatározásakor a legfontosabb 
módszer, amely szerint a standard deviáció és a 
kalibrációs görbe meredekségének a hányadosát 
3,3-del szorozva a DL-et 10-zel szorozva pedig a 
QL-et határozhatjuk meg.
DL = 3,3 σ /S,
QL = 10 σ /S,
ahol a 
σ = standard deviáció és az  
S = a kalibrációs egyenes meredeksége.
Kísérleti rész
Anyagok
A felhasznált anyagok a következők voltak: klo-
pidogrel hidrogén-szulfát, ibuprofen, meloxi kám, 
piroxikám (EGIS, Budapest); gemfi brozil, laci dipin, 
loratadin (TEVA, Debrecen); nifl uminsav (Richter 
Gedeon, Budapest); tenoxikám (Roche, Magyaror-
szág); lidokain és teofi llin (Hungaropharma).
Módszer
Az amorf minták elkészítéséhez, és azok vizsgála-
tához DSC 821e (Mett ler-Toledo, Svájc) készüléket 
használtunk, 4,8-5,2 mg tömegű mintákkal. A fű-
tési sebesség 10 °C/min volt. A mérés kezdeti és 
végső hőmérsékletének anyagonként különbözőt 
választott unk azok olvadáspontjától függően, úgy 
hogy az anyag minden esetben teljesen megolvad-
jon, de ne szenvedjen bomlást. 
A kiindulási kristályos mintát fedett , lyukasztott  
standard alumínium tégelyekbe helyeztük. Az első 
fűtés során a mintát olvadáspontja felé hevített ük, 
majd a teljes olvadás után visszahűtött ük szobahő-
mérsékletre 45 ± 5 °C/min hűtési sebességgel. Ez-
után azonnal újra felfűtött ük, és a kapott  eredmé-
nyeket elemeztük. A második fűtés kezdeti hőmér-
sékletét úgy határoztuk meg, hogy a mérés a Tm 
Kelvinben mért 2/3-ánál kisebb értékről induljon.
Eredmények
A kapott  eredmények alapján két csoportba sorol-
hatjuk a 13 vizsgált anyagot. Az első csoportba 
tartoznak azok az anyagok, amelyeknek amorf 
formáját nem sikerült előállítani. A második cso-
portba pedig azok az anyagok, amelyeknél el tud-
tuk érni az üveges állapotot. Az első csoportot a 
teofi llin DSC diﬀ raktogrammján keresztül mutat-
juk be (2. ábra). Az ábrán a két fűtés során kapott  
görbék láthatóak. Az első fűtés során (A) kapott  
endoterm csúcs, amely az olvadást jelzi, a máso-
dik fűtés (B) alkalmával is megjelent. Habár a gör-
be alatt i terület a második fűtéskor némiképp 
csökkent, ami a szabályos kristályrács elvesztésé-
re, tehát amorfi zálódásra utalhat, tehát Tg-t nem 
tudtunk detektálni. Ezek alapján kijelenthető a Tg/
Tm arányt alapul véve, hogy a teofi llin rosszul 
amor fi zálódik. A 13 vizsgált anyag közül a tenoxi-
kám, a mannit, a nifl uminsav, a teofi llin és a 
lidokain került ebbe a csoportba. Az ilyen anya-
gok formulálása során nem számíthatunk számot-
tevő amorfi zálódásra.
A második csoport anyagait az általunk alkal-
mazott  eljárással (olvadékhűtéssel) sikerült amor-
fi zálni, a kapott  eredmények alapján az anyagokat 
két alcsoportba sorolhatjuk. Az első alcsoportba 
azok az anyagok tartoznak, amelyek Tg/Tm aránya 
elmarad 0,7-től, tehát rosszul amor fi zálódónak te-
kintjük őket. Ilyen volt az ibuprofen (3. ábra). A 
példaként bemutatott  DSC görbén látható, hogy a 
kezdetben kristályos ibuprofent az első fűtés (A) 
amorfi zálta, mivel a második fűtés (B) görbéjén 
nem látható az olvadás endoterm csúcsa. A máso-
dik fűtést -60 °C-ról indított uk, mivel a Tg a nega-
tív hőmérsékleti intervallumban volt várható. 
Ebbe az alcsoportba sorolható továbbá a me-
loxikám és a határértéken fekvő piroxikám is. Az 
ilyen anyagok formulálásakor már a kevésbé ag-
resszív behatások is amorfi zálhatják az anyagot. 
Mindezek ellenére javasolható kristályos formá-
ban történő formulálásuk, hiszen ezeket az anya-
gokat csak nehezen, nagy energia befektetésével 
lehet amorf állapotba vinni. Kristályos formulá-
2. ábra: Teofi llin DSC vizsgálata. A: az első fűtés során 
kapott  görbe, Tm(A) = 274,7 °C. B: a második fűtés során 
kapott  görbe, Tm(B) = 272,3 °C.
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lásuk során kevésbé kell számolnunk az amorf for-
ma megjelenésével.
A második alcsoport anyagainak a Tg/Tm aránya 
nagyobb, mint 0,7, így jól amorfi zálódónak tekint-
hetjük őket. A klopidogrel hidrogén-szulfát DSC 
görbéjén látszik, hogy az első fűtés során (A) az 
anyag megolvadt, majd a visszahűtést követően, a 
második fűtéskor (B) eltűnt az olvadás endoterm 
csúcsa, és megjelent az üveges átmenet (4. ábra). 
Ha kristályos végtermék a cél, akkor a formulálás 
egésze során fi gyelemmel kell kísérnünk az anyag 
szerkezetét. Ugyanakkor az így viselkedő anyagok 
esetében javasolható az amorf formában való al-
kalmazás, hiszen könnyen üveges állapotba hoz-
hatóak, és a megfelelő segédanyagokkal sokáig 
amorfak is maradnak. Ebbe a csoportba sorolható 
továbbá a lacidipin, a gemfi brozil, a szorbit, a 
loratadin és a klórhexidin is.
Az összes vizsgált anyag mérési eredményeit és 
amorfi zálhatóságát az I. táblázat foglalja össze.
Megfi gyelhető, hogy a hasonló molekulaszerke-
zetű anyagok, mint például az egyforma alapvázú 
oxikámok, vagy a szorbit és a mannit, melyek egy-
más diasztereomerei, teljesen eltérően amor fi zá-
lódnak.
Kijelenthető, hogy az esetek nagy részében a Tg 
a Tm 2/3-a illetve 4/5-e közé esett , tehát ezen értékek al-
kalmazhatóak a Tg előzetes megkeresésére. 
3. ábra: Ibuprofen DSC vizsgálata. A: az első fűtés során 
kapott  görbe, Tm=77,4 °C. B: a második fűtés során kapott  
görbe, Tg=-44,4 °C.
4. ábra: Klopidogrel hidrogén-szulfát DSC vizsgálata. A: az 
első fűtés során kapott  görbe, Tm = 181,2 °C.  B: a második 
fűtés során kapott  görbe, Tg = 87,9 °C.
I. táblázat 
A vizsgált anyagok Tm, Tg és Tg/Tm értékei
Hatóanyagok Olvadáspont(Tm ; °C)
Üvegesedési 
hőmérséklet
(Tg; °C)
Tg/Tm 
(K/K) Amorfi zálhatóság
Tg a Tm 2/3-4/5-e 
között 
Tenoxicam 22 6,0 - - rossz -
Mannit 166,9 - - rossz -
Nifl uminsav 205,4 - - rossz -
Teofi llin 271,6 - - rossz -
Lidokain   70,1 - - rossz -
Meloxikám 264,0   63,5 0,63 rossz nem
Ibuprofen   77,4 –42,5 0,66 rossz nem
Piroxikám 203,1   58,1 0,70 határérték igen
Lacidipin 184,8   54,4 0,71 jó igen
Gemfi brozil   61,5 –29,2 0,73 jó igen
Szorbit   91,4        0,77 0,75 jó igen
Loratadin 137,6   40,4 0,76 jó igen
Klopidogrel HSO4 181,2   88,9 0,80 jó igen
Klórhexidin 140,3   61,7 0,81 jó nem
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Összegzés
Végezetül kijelenthető, hogy az amorf forma jelen-
léte nagy fi gyelmet érdemel a gyógyszertechnoló-
gus részéről. Fontos amorfi zálhatósági vizsgálato-
kat végezni a formulálni kívánt ható-, illetve se-
gédanyagokon egyaránt, hiszen számos olyan 
technológiai folyamaton mennek keresztül, ame-
lyek részben vagy teljesen amorfi zálhatják az 
anyagot. Elvégeztünk egy termoanalitikai gyors-
tesztet 13 különböző anyagon, amellyel megállapí-
tott uk az amorfi zálhatóságukat. Az értékek tükré-
ben kijelenthető, hogy az amorfi zálhatósági vizs-
gálatokat minden egyes anyagnál egyedileg kell 
elvégezni, mert egymásra szerkezetileg hasonlító 
anyagoknál is jelentős eltérések adódhatnak.
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Co-grindinga b s t r a c t
Particle size reduction to the submicron region in a grinding process demands a high 
energy input. This grinding energy requirement can be reduced by means of a suitable 
additive, e.g. polymer, and performing a co-grindin g process. Although these excipients 
promote attainment of the nanoparticle size range, they can also decrease the crystallinity 
of the active pharmaceutical ingredient. Different types of polymers have different abilities 
to amorphi ze the active material. To demonstrate the amorphization effects of different 
polymers, meloxicam (MX) as a model drug was subjected to co-grinding in the presence 
of one or other of four different polymers (PEG 6000, PEG 20,000, PVP C30 and PVP K25)
and the products were investigated by XRPD, FT-IR and SEM. Although the PEG materials 
slightly melted and covered the MX particles during the grinding, they did not cause any 
changes in crystallinity. The PVP polymers softened and covered the MX particles, but dras- 
tically reduced the crystallinity of the drug. FT-IR revealed a weak secondary bonding 
between MX and the PVP polymer chain. 
 2013 Elsevier Ltd. All rights reserved. 1. Introduction 
Grinding is a technique that is widely used to decrease 
the particle size of a solid material down to the nanorange, 
with the purpose of enhancing the solubility, the dissolu- 
tion rate and the oral absorption of poorly water-solub le 
compounds [1,2]. To achieve the expected nano-siz ed 
particles, a high energy input is needed, which can be pro- 
vided by various equipme nt, such as a ball-mill, cryo-mill, 
jet-mill, and colloidal mill. A common problem with these 
methods is the high energy requiremen t: the smaller the 
particles produced, the higher the energy needed. This en- 
ergy requirement can be decreased by adding a suitable 
excipient and performi ng a co-grinding procedure [3,4].
An appropriate additive also helps to prevent the aggrega- 
tion of nanoparticl es, lubricates the system, and increases the water solubility of the active pharmac eutical ingredi- 
ent (API). Pharmaceut ical excipients include several mate- 
rials which meet the requiremen ts, but most of them are 
polymers. The most widely used as grinding materials 
are polyethylene glycol (PEG) and polyvinylpy rrolidone 
(PVP).
The various PEGs are used in the pharmaceuti cal indus- 
try as binders, carriers, lubricants, etc., thanks to their 
advantageous propertie s: PEGs are completely biocompat- 
ible, they can exhibit a combination of hydrophilic and 
lipophilic properties and they are commerciall y available 
in various molecula r weights. As semi-crystal line materi- 
als, they have melting points in the range from 3 to 
68 C, depending on the molecular weight [5,6]. Their 
importance in pharmac eutical research is increasing, in 
consequence of their ability to enhance the dissolution rate 
of numerous poorly water-so luble drugs [7,8].
PVP is also produced in various molecula r weights and 
particle sizes. These materials are mostly used as binders, rind ing 
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and stabilizer s. In the literature PVP has often been used 
as an additive during co-grinding, serving as a carrier or 
to prevent aggregation [9,10]. It has also been demon- 
strated that it can decrease the crystallinity of API during 
methods providing high energy [11–13].
We earlier veriﬁed that PEG and PVP can be applied as 
suitable additives to decrease the energy requirements of 
grinding, to help reduce the particle size to the nanorange, 
to prevent the aggregation of nanoparticl es and to increase 
solubility [14]. In that study, the API was ground in the 
presence of two types of PVPs and PEGs. All four additives 
helped to reduce the mean particle size to the nanorange. It 
was shown that the polymers exerted different inﬂuences
on the crystallinity of the API, and the dissolution rate of 
the nano-siz ed API was also improved to different extents. 
The aim of our present research work was to investigate 
the effects of different polymers on the crystallinity of a
model material during co-grinding. MX was selected as 
model API, and the polymers were two types of PVP and 
two types of PEG. We set out to quantify the decrease in 
crystallinity in time and to detect any bonding formed be- 
tween the MX and the polymers. 
MX is a non-stero idal anti-inﬂammatory drug that is 
main by applied in therapy as an anti-inﬂammatory and 
strong analgetic agent [15]. MX is practically insoluble in 
water while it displays a relatively high permeabilit y
through cell membranes. It was chosen as model com- 
pound because it is capable of hydrogen-b ond to other 
materials.2. Materials and methods 
2.1. Materials 
Pur e cry st al li ne MX (4-h yd ro xy -2 -m et hy l- N- (5- me th yl -
2-t hi az ol yl )-2H -b en zot hia zi ne- 3- car bo xa mi de -1 ,1 -d io xi de )
was pu rc has ed fro m EG IS Lt d. (Bu da pe st , Hu nga ry ). The po ly -
me r ad di ti ves th at we re us ed as gr in di ng ex ci pi en ts wer e PVP 
K25 wit h a mo le cul ar wei gh t of 34 ,0 00 an d PVP C30 wi th a
mo le cu la r we ig ht 58 ,00 0) fro m BA SF (Ludw ig sh afe n, 
Ger ma ny ), and PE G wit h mo le cu la r wei gh ts of 60 00 an d
20, 00 0 fro m Si gm a–Al dr ic h Ch emi e Gm bH , Münch en, 
Ger ma ny .
2.2. Grinding process 
Physical mixtures of MX, as active pharmaceuti cal 
ingredient, and the grinding (stabilizer) polymer (PEG
6000, PEG 20,000, PVP K25 or PVP C30) were prepared 
and charged into the stainless steel jar of a planetary ball 
mill containing 10 stainless steel balls (Retsch PM 100, 
Retsch GmbH & Co., Haan, Germany ). The mass ratios were 
based on previous work [14], so as to give nanoparticl es 
(200–600 nm). For the PVPs, the drug: excipient mass ratio 
was 1:1, while for the PEGs it was 1:2. 
Mixtures were ground for 140 min, samples being with- 
drawn for investiga tion after 20, 40, 60, 80, 100, 120 and 
140 min. During the grinding process, the temperature of 
the mortar was measure d with an infrared thermometer Please cite this article in press as: Mártha C et al. Ef fects of polymers o
process . Eur Polym J (2013), http ://dx.doi.org /10.1016/ j.eurpolym j.2013right before sample withdrawal. The temperature of the 
mortar was not higher than 56 C through milling. 
2.3. X-ray powder diffraction (XRPD)
XRPD analysis was performed with a Bruker D8 Ad- 
vance diffractometer (Bruker AXS GmbH, Karlsruhe, Ger- 
many) system with Cu K kI radiation (k = 1.5406 Å). The 
samples were scanned at 40 kV and 40 mA from 3 to 40 
2h, at a scanning speed of 0.05 /s and a step size of 
0.010. The crystallinity of the samples made with the PVPs 
as amorpho us materials was determined via the total area 
beneath the curve between 12  and 30  2h, while the 
determination s of the samples made with the semicrystal- 
line PEGs were based on the curves relating to MX alone. 
To avoid the problems caused by the particle size reduction 
and randomly oriented particles, we used an internal stan- 
dard method. This technique is widely applied for quanti- 
tative XRPD. As internal standard, we mixed 20% (w/w)
of pure crystalline NaCl into the binary mixtures. Before 
its applicati on, the particle size of the NaCl was set into 
the similar range as that of the MX (2643.6 ± 2629.1 nm).
After Ka2-stripping, background removal and smoothing 
of the areas under the peaks, the area under the peak of 
MX was proportio ned to the area under the peak of NaCl 
(31–32.5 2h). All manipulations of diffractog rams were 
performed with DIFFRACT plus EVA software. 
2.4. Fourier transform infrared (FT-IR) spectroscopy 
FT-IR spectra were recorded with a Bio-Rad Digilab 
Division FTS- 65A/896 FTIR spectrometer (Bio-Rad Digilab 
Division FTS-65A/ 869, Philadelp hia, USA) between 4000 
and 400 cm 1, at an optical resolution of 4 cm 1; operating 
conditions: Harrick’s Meridian SplitPea single reﬂection,
diamond, ATR accessory. Thermo Scientiﬁc GRAMS/AI Suite 
software (Thermo Fisher Scienciﬁc Inc., Waltham, USA)
was used for the spectral analysis. 
For FT-IR determination s, the ATR method was chosen, 
because with this there is no need for sample preparation, 
such as particle size reduction or KBr tableting, which 
would expose the samples to further physical stress. 
2.5. Scanning electron microscopy (SEM)
The morphology of the particles was examined by SEM 
(Hitachi S4700, Hitachi Scientiﬁc Ltd., Tokyo, Japan). A sput- 
ter coating apparatus (Bio-Rad SC 502, VG Microtech, Uck- 
ﬁeld, UK) was applied to induce electric conductivi ty on the 
surface of the samples. The air pressure was 1.3–13.0 MPa. 
Brieﬂy, the samples were sputter-coa ted with gold–palla- 
dium under an argon atmosphere, using a gold sputter 
module in a high-vacuum evaporator and the samples were 
examined at 10 kV and 10 lA. Meloxicam particle diameter 
distribution s were obtained by analyzing several SEM 
images with the ImageJ software environment. 
2.6. Dissolution studies 
The dissolution of physical mixtures and samples with- 
drawn after 140 min of grinding were determined n the crys tallinity of nanonized melo xicam during a co-grind ing 
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Fig. 1. XRPD diffractograms of MX made with PEGs; (a) MX:PEG 6000 (1:2); (b) MX:PEG 20,000 (1:2).
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paddle method (Pharma test Heinburg, Germany), where 
a paddle was rotating in the dissolution vessel with speed 
of 100 rpm. All the samples containe d 10 mg of the drug. 
The dissolution medium was 100.0 mL of phosphate buffer 
solution (pH 6.8 ± 0.1) at 37 ± 0.5 C. 1 mL samples were 
withdrawn and immediatel y ﬁltered (cut-off 0.2 lm, Min- 
isart SRP 25, Sartorius, Germany) and the amount of dis- 
solved drug was determined with spectrophotom etrically 
(k = 364 nm). Taken samples were replaced with 1 mL of 
fresh medium. 
Drug content determinati on was carried out in 
100.0 mL of phosphat e buffer solution (pH 6.8 ± 0.1) at 
37 ± 0.5 C. Samples containing 10 mg of MX were stirred 
for 24 h. The solution was investigated by spectrophot om- 
eter (k = 364 nm).3. Results and discussion 
3.1. X-ray diffraction 
Figs. 1 and 2 show the diffractogra ms of the samples 
prepared. In each graph, the characterist ic peaks of MX Fig. 2. XRPD diffractograms of MX made with PVPs;
Please cite this article in press as: Mártha C et al. Effects of polymer s o
proc ess. Eur Polym J (2013), http ://dx.doi. org/10.1016/ j.eurpoly mj.2013can be observed. As PEG is semi-crystal line, it gives a large 
peak, with a considerable full width at half-maxim um, 
while PVP is fully amorphous, so it does not yield any sig- 
nal in the diffractogra ms. At 31.6  2h, the speciﬁc peak 
relating to NaCl appears. Each ﬁgure shows the changes 
in crystallinity with time. Fig. 1a (PEG 6000) and b (PEG
20,000) demonst rate that no amorphizat ion occurred dur- 
ing the co-grinding process: the areas under the peaks did 
not decrease radically. The samples prepared with the PVPs 
behaved differently: the areas under the peaks continu- 
ously decreased as the grinding time was lengthen ed 
(Fig. 2a (PVP C30) and b (PVP K25)). Although the drugs 
were not converted completely into the amorphous form, 
because the diffractogra ms exhibited small peaks in the 
amorphous halo, the change in crystallinity was drastic. 
During the co-grindi ng process, no other polymorphic form 
of MX appeared: no shift in the peaks and no new peaks 
were observed in the pattern. 
To quantify the changes in time, the areas underneath 
the diffractograms were determined between 12  and 30 
2h after Ka2-stripping, background removal and curve 
smoothing. The areas under the peaks relating to MX were 
divided by the areas under the peaks of NaCl. These values  (a) MX:PVP K25 (1:1); (b) MX:PVP C30 (1:1).
n the crys tallinity of nanonized meloxicam during a co-grind ing 
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Fig. 3. Crystallinity changes of the samples. 
Fig. 4. FI-IR spectras of the samples made with PVP C30. Arrows show the 
increasing intensity at 3400–3500 cm -1 and between 3000 and 
2800 cm 1.
Fig. 5. FI-IR spectras of the samples made with PVP K25. Arrows show the 
same intensity changes as in case of PVP C30 at 3400–3500 cm -1 and 
between 3000 and 2800 cm 1.
Fig. 6. FI-IR spectras of the samples made with PVP C30. The arrows point 
the changes related to secunder-amid groups. Increasing intensities can 
be observed around 1620 cm 1 (mCONH) and between 1550 cm 1 and 
1530 cm 1 (mNH).
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changes based on the areas under the peaks. The samples 
made with the PEGs did not undergo any amorphization .
The long-range order of molecular packing remained. The 
diversity of the values may be caused by the variation in 
particle size, and the orientation of the larger particles .
Samples involving the use of PVPs as grinding material lost 
their well-deﬁned molecula r conformation. The areas un- 
der the peaks decreased on increase of the grinding time. 
For PVP C30 and PVP K25, 12.23% and 15.66% of the MX re- 
mained in crystalline form at the end of the grinding pro- 
cess. To determine the difference between the rates of 
amorphizat ion of the two different samples, logarithms 
were calculated (Fig. 3). The resulting plots were linear, 
and the diversity of the crystallinity could be observed Fig. 7. FI-IR spectras of the samples made with PVP K25. Same changes 
can be observed as in case of PVP C30 at 1620 cm 1 and between 
1550 cm 1 and 1530 cm 1.
n the crys tallinity of nanonized melo xicam during a co-grind ing 
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tion relating to the samples made with PVP C30 was stee- 
per (0.0171) than that for those made with PVP K25 
(0.0127), which means that the use of PVP C30 as grind- 
ing material causes faster amorphizat ion. 
3.2. FT-IR spectroscopy 
To determine whether any decomposition occurred 
during the grinding process and to search for any possible 
bonding between the API and the polymers, FT-IR spectros- 
copy was carried out. This proved that no disintegr ation 
took place in any of the samples. The characteristic bands 
of MX were seen in all of the curves. 
No measurable changes were observed in the case of 
the products made with the PEGs. No shifts no changes 
in band shape and no new bands were detected in the 
curves. This means that bonds between the materials were 
not created by grinding. Changes in the intensities of the 
peaks can be explained by the decreasing particle size of 
the products. 
The samples made with the PVP polymers exhibited 
several changes in the spectra during the grinding process 
(Figs. 4 and 5), most signiﬁcantly in the interval 3725–
2600 cm 1. At 3400–3500 cm -1, the intensity of the associ- 
ated mOH mode increased with increasing grinding time. A
similar increase was observed in the range of CH and NH 
valence vibrations, between 3000 and 2800 cm 1. The sep- 
aration of the two ranges is impracticabl e. 
The most signiﬁcant changes for both excipients are re- 
lated to the secondar y amide group of MX. Increases inten- Fig. 8. SEM photomicrographs of samples made with PEG 6000 (‘‘A’’ physical mi
‘‘D’’ sample ground for 140 min).
Please cite this article in press as: Mártha C et al. Effects of polymer s o
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between 1550 cm 1 and 1530 cm 1 (mNH). Further, the 
intensity relating to a hybrid stretching mode at around 
1440 cm 1 is increased and a shoulder grows around 
1390 cm 1 (Figs. 6 and 7).
All these alteration s point to the presence of weak 
bonding between the carboxyl group of MX and the poly- 
mers, which is able to help the molecule s to separate from 
each other and keep them in this (not well-deﬁned)
conformation.
3.3. SEM 
Differences between the abilities of the polymers to de- 
crease the crystallinity of MX can also be seen in the SEM 
photomicro graphs. Fig. 8 presents SEM pictures of physical 
mixtures and samples (ground for 140 min) made with 
PEG 6000 and PVP C30. The PEGs have relatively low melt- 
ing points, which were exceeded during the co-grinding 
process (the temperat ure of the mortar was not higher 
than 55 C). The polymers are locally melted by the impact 
and friction of the balls in the mortar. Reduced-sized MX 
particles can be observed in the melt of the polymer. These 
particles are in the nanorang e. The same phenomeno n can 
be observed the samples made with PEG 20,000. 
PVPs are amorphous polymers, and did not melt during 
the milling process. The temperature was locally higher 
than the Tg of the excipients, so the polymers softened 
and coated the amorphized MX. These MX particles more 
or less preserved their contour while they were decreased 
to the nanolevel. xture, ‘‘B’’ sample ground for 140 min) and PVP C30 (‘‘C’’ physical mixture, 
n the crys tallinity of nanonized meloxicam during a co-grind ing 
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Fig. 9. MX particles, water soluble polymer additives: PEG 6000 ‘‘A’’; and PVP C30 ‘‘B’’ removed. 
Fig. 10. Dissolution extents of pure MEL, physical mixtures and solid 
dispersions made with PVPs, withdrawn after 140 min of grinding. 
Fig. 11. Dissolution extents of pure MEL, physical mixtures and solid 
dispersions made with PEGs, withdrawn after 140 min of grinding. 
6 C. Mártha et al. / European Polymer Journal xxx (2013) xxx–xxxTo identify the habit of the MX particles formed by the 
co-grinding with the polymers, the water-soluble excipi- 
ents were extracted from the system by washing-out with 
cold distilled water and the material was centrifuged three 
times. By this method, the water-insoluble MX (solubility
meloxicam is 4.4 ± 0.7 lg/mL [16]) can be observed indi- 
vidually. The SEM images of the samples made with PEG 
(Fig. 9A) revealed well-formed crystalline MX particles 
with sharp edges. The shape and position of the particles 
indicate recrystal lization. The MX molecules can dissolve 
into the melted PEG polymer, but immedia tely following 
the decrease of temperature, the MX precipita ted out from 
the dispersio n, forming crystalline particles. The samples 
made with the PVPs did not give sharp lines, but formed 
a shapeless amorphous mass. 3.4. Dissolution studies of prepared samples 
Drug content determination showed, that actual drug 
content of each samples were 94.23% (±2.63%) of the theo- 
retical drug content. 
Dissolution studies of the samples showed that physical 
mixtures of MX and polymers have a similar dissolution 
proﬁle as the pure MX (particle size of raw MX: dSEM:
2643.6 ± 2629.1 nm). All mixtures made with PVPs and Please cite this article in press as: Mártha C et al. Ef fects of polymers o
process . Eur Polym J (2013), http ://dx.doi.org /10.1016/ j.eurpolym j.2013PEGs showed slightly higher and faster solubility. The dis- 
solution of samples made with PVPs and ground for 
140 min in the ﬁrst 5 min was 50 times greater than 
the dissolution of the correspondi ng physical mixtures. 
After 120 min more than 90% of the MX was dissolved in 
the media (Fig. 10 ). In case of samples with PEGs the disso- 
lution was also higher, the extent of dissolution after 
30 min was more than 60% (Fig. 11 ). The particle size of 
MX in the samples were: MX-PVP K25: dSEM:
246.4 ± 108.5 nm; MX-PVP C30: dSEM: 140.4 ± 69.2 nm; 
MX-PEG 6000: dSEM: 229.5 ± 92.3 nm; MX-PEG 20000: 
dSEM: 234.5 ± 122.9 nm. That means that the amount of re- 
leased MX depends on the particle size of MX in the sample 
and also on the crystal structure , because the amorphous- 
nano-MX-P VP dispersio ns had a greater dissolution rate 
than the crystalline-nan o MX-PEG compositions .4. Discussion 
The present work has demonstrated that the polymers 
used to reduce the grinding energy during co-grindi ng to 
nanoparticl es can decrease the crystallinity of MX. These 
polymers have different abilities to convert the drug into 
amorphous form. XRPD measureme nts proved that the 
two different types of PEG did not have a signiﬁcant effect n the crys tallinity of nanonized melo xicam during a co-grind ing 
.03.0 06 
C. Mártha et al. / European Polymer Journal xxx (2013) xxx–xxx 7on the crystallinity of MX, while the two different types of 
PVP decreased it drastically. Weak secondar y bonding be- 
tween MX and the PVPs was found by FT-IR and under 
these certain circumstances no degradat ion or decomposi- 
tion occurred to MX. SEM images conﬁrmed the major par- 
ticle size decrease and the differenc es in crystal behavior of 
the samples made with the different polymers. All the 
ground samples exhibited a higher and faster dissolution 
rate, while the amorphous-na no-MX-PVP solid dispersions 
had an intense immediate dissolution. Acknowled gements 
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Abstract Particle size reducing methods demand high
energy input, so during these procedures crystallinity
change always can occur. These changes can be enhanced
by additives, which are often used to improve the disso-
lution, the powder rheological properties or the process-
ability of the API (active pharmaceutical ingredient), or to
support the particle size reduction. Different materials act
differently during these crystallinity changing methods:
some materials are easy to amorphize, while some of them
can be really resistant. In this work, two chemically
equivalent sugar alcohols as model materials—b-D-man-
nitol as poor glass former and D-sorbitol as good glass
former—were chosen to be co-ground with polymeric
additives (PVP C30 and PEG 6000). During the 120 min
milling process mannitol showed just minor change in
crystallinity alone or with PEG. But milled with PVP some
amorphization was found. Sorbitol suffered noteworthy
changes in crystallinity: raw sorbitol lost its crystallinity
during the milling, and also polymorphic transition was
displayed. Same transition happened during the milling
with PVP: the whole crystallinity of the sorbitol decreased,
while the amount of gamma polymorph increased. During
the co-grinding with PEG, the polymer prevented the
amorphization of sorbitol and kept the well-ordered crystal
structure of the material.
Keywords Mannitol  Sorbitol  Polyethylene glycol 
Polyvinylpyrrolidone  Crystallinity  Co-grinding
Introduction
Grinding or milling is a technique that is widely used in
pharmaceutical technology to increase the dissolution rate,
the solubility, and the oral absorption of poorly water-sol-
uble compounds [1–3]. Milling is also used to improve the
processability and powder rheological properties of solid
materials by formulating a spherical shape and enhancing
the specific surface of the particles [4]. However, the
accompanying high energy intake often causes major
changes in the crystal structure of materials [5–7].
Mechanical activation can either break down the long-range
order of the molecular packaging and turn the material into
an amorphous form [8] or alter the order of the lattice
structure and cause a polymorphic transition [9, 10]. This
new arrangement is either stable or can recrystallize to the
initial state during storage.
To reduce the high energy need, which is a general
problem in particle size-reducing processes, suitable addi-
tives are used. These additives are able to reduce the
friction between the particles and the milling device, and
thereby they decrease the energy expended in grinding
[11]. An appropriate additive can also avoid the aggrega-
tion of small particles by reducing the surface tension and
the electrostatic charge. Moreover, the presence of these
excipients can cause changes in crystallinity [12, 13]. For
example polymers can adsorb drugs on their surface, or
they can form co-crystals, eutectic mixtures or complexes.
To investigate the behaviour of organic drugs with
low molecular mass during the milling process we
chose simple and cheap sugar alcohols, b-D-mannitol and
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D-sorbitol. Both are widely used in pharmaceutics as
sweeteners, bulking agents or moisture stabilizers [14–16].
Both are stable and inert compounds, which are those
properties that make them a good choice as excipients
during tableting, freeze-drying, capsulizing, granulating or
grinding [17–20]. They are often used together as carrier
additives usually in pulmonary delivery systems [21]. Both
can exist in many polymorphic-, solvate-, hydrate- and
amorphous forms (mannitol has three stable polymorphs
and sorbitol has 5) [22, 23].
Polyvinylpyrrolidone (PVP) is a fully amorphous poly-
mer that is commercially available in various molecular
masses and particle sizes. In pharmaceutics it is mostly
used as binder, matrix polymer, disintegrant, crystallization
inhibitor and stabilizer [24, 25]. It has been demonstrated
that PVP is capable of decreasing the milling energy, while
as a carrier it increases solubility in water [25, 26].
Polyethylene glycols (PEGs) are used in the pharma-
ceutical industry as binders, carriers, lubricants, etc. These
semi crystalline excipients are water-soluble and com-
pletely biocompatible. They can be purchased in various
molecular masses with different melting points [27, 28].
PEGs are able to reduce milling energy and enhance the
water solubility of poor water-soluble drugs.
It has been reported that the ratio Tg/Tm (K/K) can serve
as an appropriate value from which the glass-forming
properties of materials can be inferred. If the value of this
ratio is lower than 0.7 the given material is a poor glass-
former, whereas if the value is higher than 0.7, the material
is very likely a good glass-former [29–32].
In the present work, we investigated the influence of
grinding and co-grinding with the polymer excipients, PVP
and PEG, on crystallinity of the two common sugar alcohols,
mannitol and sorbitol. These materials were chosen because
they have similar chemical structures—they are diastereo-
mers—but different glass-forming properties. In this rela-
tion, the investigated samples were monitored by XRPD and
DSC techniques for the first time to our best knowledge.
Materials and methods
Materials
For our investigation two sugar alcohols were used:
b-D-mannitol ((2R,3R,4R,5R)-Hexan-1,2,3,4,5,6-hexol) and
D-sorbitol ((2S,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol). Both
materials were purchased from Hungaropharma (Budapest,
Hungary), which met the quality requirements of Ph.Eur.8.
PVP C30 (with a molecular mass of 58,000) which was
obtained from BASF (Ludwigshafen, Germany) and PEG
6,000 from Sigma-Aldrich Chemie GmbH, Mu¨nchen,
Germany, were used as grinding excipients.
Grinding process
Physical mixtures of the crystalline sugar alcohols (man-
nitol and sorbitol) and stabilizer polymer additives (PVP
C30 and PEG 6,000) were prepared and charged into a hard
polyamide mortar. Equal amounts of agate balls were also
placed into the chamber. The mass ratio of the mixtures
was 1:1 in all cases. The grinding processes were carried
out with a FRITSCH–Pulverisette planetary ball mill.
Mixtures were ground for 120 min, samples being
withdrawn for investigation after 20, 40, 60, 80, 100 and
120 min.
X-ray powder diffraction (XRPD)
XRPD analysis was performed with a Bruker D4 diffrac-
tometer (Bruker AXS GmbH, Karlsruhe, Germany) system
with Cu K kI radiation (k = 1.5406 A˚). The samples were
scanned at 40 kV and 40 mA from 3 to 40 2h, at a
scanning speed of 0.05s-1 and a step size of 0.010. The
crystallinity of the samples was determined as ratio
between areas beneath characteristic and separate peaks of
physical mixtures and samples and was expressed as per-
centage (%). These peaks are specific for each material;
none of them is a double peak, or covered by the peak of
the semi crystalline PEG. All manipulations of diffracto-
grams and the calculation of area under curves were per-
formed with DIFFRACTplus EVA software.
Differential scanning calorimetry (DSC)
DSC data were recorded with a Netzsch STA-409 (Selb,
Germany) instrument with an intercooler. 4.5–5.5 mg sam-
ples were crimped in aluminium pans with two holes and
were examined in the temperature interval 298.15–473.15 K
under an argon gas flow at 100–150 mL min-1, heating rate
was 10 K min-1.
Results and discussion
Determination of crystallinity of mannitol
The DSC measurements indicated that the ratio Tg/Tm (K/K)
for pure b-D-mannitol (Tg 285.75 K Tm 440.05 K) is lower
than 0.7, suggesting that this compound has only a low
tendency to exist in amorphous form. b-D-mannitol has
linear molecules and an orthorhombic crystal structure,
which is preferable for the development of strong long-range
order among the molecules.
Thermoanalytical techniques such as DSC or DTA are
suitable methods for investigation of the crystallinity of
samples. From the areas under the peaks of melting of the
2480 C. Ma´rtha et al.
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samples can be concluded. DSC measurements demon-
strated that the raw mannitol during the grinding process
did not suffer any loss in crystallinity, and it exhibited a
similar characteristic melting peak at the same temperature
(440.05 ± 3.1 K), with identical enthalpy (DH = 41.02 ±
1.13 J g-1) as for raw mannitol itself. The mannitol sam-
ples made with polymer additives behaved similarly to
pure mannitol: the amorphous PVP has no peak in the DSC
curve, while the semi crystalline PEG has a broad melting
peak at around 338 K; the mannitol in the mixtures dis-
played identical melting action to that without polymers.
Specific peaks relating to the melting point of mannitol
appeared in the curves with slightly varying enthalpy
(DH = 22.04 ± 0.83 J g-1) indicating that the mannitol
maintained it well-defined long-range order in the crystal
structure.
XRPD measurements can also be used to investigate the
crystal structure of ingredients. As it was shown before the
limit of quantification (LOQ) of XRPD methods is low
enough to use it for quantitative measurements. In case of
clopidogrel bisulphate polymorphs and olanzapine poly-
morphs the LOQ were 1.0–1.5 % (w/w) and 1.22 % (w/w),
respectively [33, 34]. The areas under diffraction peaks are
related to the crystallinity from the changes of the inde-
pendent characteristic peaks the decrease of crystallinity
can be calculated.
XRPD measurements were performed on each of the
raw materials and samples. Amorphous PVP exhibited a
halo with no specific peaks in the diffractogram, PEG, as a
semi crystalline polymer gave few broad peaks in the
investigated range (Fig. 1). Pure mannitol displayed peak
characteristics of the b-D form (sharp peaks at the fol-
lowing 2h values: 10.441, 14.572, 18.722, 21.019,
23.374, 28.282, 29.444, 31.728, 38.645, 44.052).
After 120 min of grinding, the same peaks were found in
the curve. No shifts were observed, no peaks disappeared
and no new peaks appeared. The areas under peaks at
9.5–11 2h; 13.7–15.5 2h and 17.7–19.9 2h were calcu-
lated for each sample that were withdrawn. This revealed
that, although some peaks decreased to an insignificant
extent, no fundamental change in crystallinity occurred
during grinding (Fig. 2).
Same grinding and investigation method was applied in
the presence of the polymer additives. The samples con-
taining PEG gave the peaks characteristic of mannitol and
the broad peak relating to PEG at around 22–24 2h. Crys-
tallinity determination (based on the same peaks as utilised in
the case of raw mannitol) proved that minor amorphization
took place after 40 min of milling. No polymorph transition
was observed: no peaks underwent a shift or disappeared and
no new peaks were detected. Slightly different behaviour
was observed for the samples containing PVP. The peaks
were specific for mannitol, but the areas under the curves
decreased with increasing grinding duration. The degree of
this decrease exceeded the quantification limit and could not
be interpreted in terms of a decrease in particle size. The
change in crystallinity did not exceed 70 % during the
milling. After 40 min of grinding an apparent equilibrium set
between the crystalline and amorphous phases.
Crystallinity determination of sorbitol
The ratio Tg/Tm (Tg and Tm in K) measured for D-sorbitol
was 0.75 (Tg 273.92 K Tm 364.55 K), which predicted this
material is a good glass-former.
The DSC measurements showed that the sorbitol used
was a mixture of the epsilon (Tm 364.55 K) and gamma
(372.05 K) polymorphs. During the grinding process, the
proportions of the polymorphs changed. The pure material
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Fig. 1 X-ray diffractograms of
pure PVP C30, PEG 6000, and
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ground for 120 min with PVP
C30 and PEG 6000
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contained a predominance of the epsilon form. The milling
led to a decrease in the amount of the epsilon form, while
the amount of the gamma polymorph slightly increased
(Fig. 3). This means that the mechanical energy broke
down the crystal structure of the crystalline epsilon sorbi-
tol. Some of the amorphous material recrystallized due to
the mechanical impact.
A similar phenomenon was observed in the DSC curves
of sorbitol co-ground with PVP. The melting point of the
sorbitol was lowered by the polymer excipient. Both poly-
morphs gave characteristic DSC curve. Similarly as when no
additive was present, the epsilon polymorph amount
decreased during the milling. In this case, the content of
gamma polymorph also decreased, as demonstrated by the
decrease of the area under the curve. The bulk part of the
system lost its well-defined long-range order of the crystal
structure.
The DSC investigation of sorbitol samples containing
PEG did not show any significant change in crystallinity.
The melting point of the semi crystalline polymer and the
melting of sorbitol were to be seen in the curves. The areas
under the melting peak of sorbitol varied only slightly
during the milling (DH = 25.04 ± 1.25 J g-1), within the
error of the measurement. No amorphization or polymor-
phic alteration was noted during the milling of these two
materials.
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To investigate the change in crystallinity of the co-ground
sorbitol and to calculate the extent of amorphization, XRPD
method was also carried out on the samples (Fig. 4).
The peaks of X-ray diffractograms of pure sorbitol were
mostly characteristic of the epsilon form, though the peaks
of the gamma form were also present. The determination of
the polymorphs was based on the calculated X-ray powder
diffractograms to be found in Cambridge Crystallographic
Data Centre (CCDC). During the milling process the areas
under the peaks relating to the epsilon form noticeably
decreased with milling time. In parallel the peaks of the
gamma polymorph became slightly larger at a similar rate.
This phenomenon which affected slightly more than 20 %
of the ground sorbitol could occur in two ways: mechanical
energy converted some of the material into the amorphous
phase and the gamma form recrystallized from this; or the
epsilon form was transformed directly to the gamma form.
A similar polymorph transition took place during the
grinding of sorbitol with PVP: peaks relating to both
polymorph forms were found in the diffractogram of the
physical mixture. During the milling process the areas
under the peak characteristics of the epsilon form
decreased markedly (Fig. 5). From the areas under the
peaks of the epsilon form at 9.5–11 2h, 23.15–24.53 2h
and 28.2–29.6 2h, the degree of reduction in crystallinity
was measured (Fig. 6). During the first 40 min the system
lost about 50 % of its well-defined crystal structure. After
40 min there was an apparent lag phase. At the end of the
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milling, slightly more than 30 % of the sorbitol remained
in the epsilon polymorph form. Most of the remaining
70 % had lost its well-defined order of molecular packing
and a minor part had been transformed into the gamma
polymorph (Fig. 7). Only the peak at 11.5–12.1 2h is
related clearly to the gamma form. All the other peaks were
characteristic either of epsilon form or of both polymorphs.
This gamma sorbitol peak was used to evaluate the poly-
morphic transition. Figure 8 illustrates the decrease in the
epsilon form and the increase in the gamma form with the
milling time. The figure has two ‘‘y’’ axes scaled differ-
ently to demonstrate the similar courses of the changes in
proportions of the two polymorphs. There was a strong
decrease in epsilon form initially, which was accompanied
by a comparable rapid increase in the gamma form. After
apparent lags, phase between 40 and 80 min both changes
(increasing of gamma and decreasing of epsilon from)
continued similarly. This polymorph alteration was con-
firmed by the changes in the other peaks. Whereas the
peaks clearly relating to the epsilon form (for example
those at 23.15–24.53 2h and 28.2–29.6 2h) decreased
continuously with the grinding time, the common peaks (at
18.1–19.1 2h) diminished only slightly. All the changes
observed are indicative of a constant crystallinity decrease
as the milling time becomes longer, some of the sorbitol
recrystallizing and changing into the gamma polymorphic
form during the process.
The samples containing PEG displayed different
behaviour during mechanical activation. The degree of
crystallinity changed by around 100 % during the overall
procedure. The sorbitol did not suffer any loss in crystal
structure. As the sorbitol itself, in the absence of excipient
did lose its crystallinity noticeably, it can be concluded,
that PEG stabilized the crystal structure of this sugar
alcohol and helped it maintain its crystallinity. No poly-
morphic transformation was detected in the X-ray pattern.
Discussion
Our study highlighted the problem that analogous materials
can react differently to a high energy impact and therefore
it can alter their physical and physical–chemical properties
so critically, that can exclude their use as a pharmaceutical
additive. Two chemically equivalent sugar alcohols (man-
nitol and sorbitol), as model materials, were subjected to
milling both alone and in presence of polymer excipients
(PVP C30 and PEG 6000) to accentuate the different
behaviour of analogous materials. As a poor glass-former
mannitol did not show any decrease in crystallinity when it
was milled alone or together with PEG. In presence of PVP
the crystal structure of mannitol was slightly lost. When
ground alone or together with PVP, sorbitol suffered
amorphization and underwent polymorph transformation
when co-ground together: the initial mostly epsilon form
continuously transited into gamma form, while parallel lost
more than 70 % of its crystallinity. PEG preserved the
well-ordered molecular packing of sorbitol and stabilized
the crystal structure therefore the sorbitol could not
amorphize. It can be concluded that these sugar alcohols
which have the same chemical structure, went through
different rate of crystallinity loss.
Acknowledgements The work was supported by the European
Union and cofunded by the European Social Fund (TA´MOP-4.2.2.A-
11/1/KONV-2012-0035). The authors wish to acknowledge the
cooperation supported by MO¨B/DAAD. The help of Kati Bergt,
Lydia Helmdach and Kristin Wendt with the XRPD and DSC mea-
surements is gratefully acknowledged.
References
1. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanoization
strategies for poorly-water soluble drugs. Drug Discov Today.
2011;16:354–60.
2. De Jong WH, Borm PJA. Drug delivery and nanoparticles:
applications and hazards. Int J Nanomed. 2008;3(2):133–49.
3. Kurti L, Kukovecz A, Kozma G, Ambrus R, Deli MA, Szabo-
Revesz P. Study of the parameters influencing the co-grinding
process for the production of meloxicam nanoparticles. Powder
Technol. 2011;212(1):210–7.
4. Mallick S, Pattnaik S, Swain K, De PK, Saha A, Ghoshal G,
Mondal A. Formation of physically stable amorphous phase of
ibuprofen by solid state milling with kaolin. Eur J Pharm Biop-
harm. 2008;68:346–51.
5. Sharma P, Denny WA, Garg S. Effect of wet milling process on
the solid state of indomethacin and simvastatin. Int J Pharm.
2009;380:40–8.
6. Brodka-Pfeiffer K, Langguth P, Grafi P, Hausler H. Influence of
mechanical activation on the physical stability of salbutamol
sulphate. Eur J Pharm Biopharm. 2003;56:393–400.
7. Yonemochi E, Kitahara S, Maeda S, Yamamura S, Oguchi T,
Yamamoto K. Physicochemical properties of amorphous clari-
thromycin obtained by grinding and spray drying. Eur J Pharm
Sci. 1999;7:331–8.
8. Ma´rtha C, Ku¨rti L, Farkas G, Jo´ja´rt-Laczkovich O, Szalontai B,
Gla¨sser E, Deli MA, Szabo´-Re´ve´sz P. Effects of polymers on the
crystallinity of nanonized meloxicam during a co-grinding pro-
cess. Eur Polym J. 2013;49:2426–32.
9. Lin SY, Hsu CH, Ke W. Solid-state transformation of different
gabapentin polymorphs upon milling and co-milling. Int J Pharm.
2010;396:83–90.
10. Chieng N, Rades T, Saville D. Formation and physical stability of
the amorphous phase of ranitidine hydrochloride polymorphs
prepared by cryo-milling. Eur J Pharm Biopharm. 2008;68:771–80.
11. Yu S, Adams MJ, Gururajan G, Reynolds G, Roberts R, Wu CY.
The effects of lubrication on roll compaction, ribbon milling and
tableting. Chem Eng Sci. 2013;86:9–18.
12. Arias MJ, Moyano JR, Gines JM. Investigation of the triamter-
ene-b-cyclodextrin system prepared by co-grinding. Int J Pharm.
1997;153:181–9.
13. Bettinetti G, Mura P, Faucci MT, Sorrenti M, Setti M. Interaction
of naproxen with noncrystalline acetyl b- and acetyl c-cyclodex-
trins in the solid and liquid state. Eur J Pharm Sci. 2002;15:21–9.
Investigation of the crystallinity of sugar alcohols 2485
123
14. Izutsu K, Yoshioka S, Terao T. Effect of mannitol crystallinity on
the stabilization of enzymes during freeze-drying. Chem Pharm
Bull. 1994;42:5–8.
15. Kim AI, Akers MJ, Nail SL. The physical state of mannitol after
freeze-drying: effects of mannitol concentration, freezing rate,
and a noncrystallizing cosolute. J Pharm Sci. 1998;87:931–5.
16. Maury M, Murphy K, Kumar S, Mauerer A, Lee G. Spray-drying
of proteins: effects of sorbitol and trehalose on aggregation and
FT-IR amide I spectrum of an immunoglobulin G. Eur J Pharm
Biopharm. 2005;59:251–61.
17. Tee SK, Marriot C, Zeng XM, Martin GP. The use of different
sugars as fine and coarse carriers for aerosolised salbutamol
sulphate. Int J Pharm. 2000;208:111–23.
18. Reitz E, Vervaet C, Neubert RHH, Thommes M. Solid crystal
suspensions containing griseofulvin—preparation and bioavail-
ability testing. Eur J Pharm Biopharm. 2013;83:193–202.
19. Gomba´s A´, Szabo´-Re´ve´sz P, Regdon G Jr, Er}os I. Study of
thermal behaviour of sugar alcohols. J Therm Anal Calorim.
2003;73:615–21.
20. Poma´zi A, Ambrus R, Sipos P, Szabo´-Re´ve´sz P. Analysis of co-
spray-dried meloxicam–mannitol systems containing crystalline
microcomposites. J Pharm Biomed Anal. 2011;10/56(2):183–90.
21. Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan
M, Mahdavi H, Nokhodchi A. Effect of carrier morphology and
surface characteristics on the development of respirable PLGA
microcapsules for sustained-release pulmonary delivery of insu-
lin. Int J Pharm. 2010;15/389(1–2):74–85.
22. Cavatur RK, Vemuri NM, Pyne A, Chrzan Z, Toledo-Velasquez
D, Suryanarayanan R. Crystallization behavior of mannitol in
frozen aqueous solutions. Pharm Res. 2002;19:6.
23. Nezzal A, Aerts L, Verspaille M, Henderickx G, Redl A. Poly-
morphism of sorbitol. J Cryst Growth. 2009;311:3863–70.
24. Martini A, Torricelli C, De Ponti R. Physico-pharmaceutical
characteristics of steroid-crosslinked polyvinylpyrrolidone co-
ground systems. Int J Pharm. 1991;75(2-3):141–6.
25. Wu JZ, Ho PC. Evaluation of the in vitro activity and in vivo
bioavailability of realgar nanoparticles prepared by cryo-grind-
ing. Eur J Pharm Sci. 2006;29(1):35–44.
26. Mura P, Cirri M, Faucci MT, Gine`s-Dorado JM, Bettinetti GP.
Investigation of the effects of grinding and co-grinding on
physicochemical properties of glisentide. J Pharm Biomed Anal.
2002;30(2):227–37.
27. Ambrus R, Aigner Z, Catenacci L, Bettinetti G, Szabo´-Re´ve´sz P,
Sorrenti M. Physico-chemical characterization and dissolution
properties of nifluminic acid-cyclodextrin-PVP ternary systems.
J Therm Anal Calorim. 2011;104:291–7.
28. Yam N, Li X, Jasti BR. Interactions of topiramate with poly-
ethylene glycol 8000 in solid state with formation of new poly-
morph. Int J Pharm. 2011;411(1-2):86–91.
29. Bailey FE, Koleske JV. Poly(ethylene oxide). New York: Aca-
demic; 1976.
30. Craig DQM, Royall PG, Kett VL, Hopton ML. The relevance of
the amorphous state to pharmaceutical dosage forms: glassy
drugs and freeze dried systems. Int J Pharm. 1999;179:179–207.
31. Yu L. Amorphous pharmaceutical solids: preparation, charac-
terization and stabilization. Adv Drug Deliv Rev. 2001;48:27–42.
32. Jo´ja´rt-Laczkovich O, Szabo´-Re´ve´sz P. Formulation of tablets
containing an ‘in-process’ amorphized active pharmaceutical
ingredient. Drug Dev Ind Pharm. 2011;37:1272–81.
33. Uvarov V, Popov I. Development and metrological character-
ization of quantitative X-ray diffraction phase analysis for the
mixtures of clopidogrel bisulphate polymorphs. J Pharm Biomed
Anal. 2008;46:676–82.
34. Tiwari M, Chawla G, Bansal AK. Quantification of olanzapine
polymorphs using powder X-ray diffraction technique. J Pharm
Biomed Anal. 2007;43:865–72.
2486 C. Ma´rtha et al.
123
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV 
Effect of Co-Grinding on Crystallinity
of Clopidogrel Bisulfate
A high energy input during pharmaceutical formulation is capable of decreasing
the crystallinity of compounds in the product. The presence of the amorphous
form can cause serious problems at any stage of the formulation. Crystallinity
changes of a model powder mixture containing clopidogrel bisulfate (CLP) and a
colloidal silicon dioxide as additive were investigated during a long-time co-grind-
ing process. The crystallinity of CLP was reduced sigmoidally by co-grinding with
longer co-grinding time. X-ray powder diffraction and differential scanning calo-
rimetry examinations confirmed that the product had become totally amorphous
after four hours of grinding. Thermogravimetric results proved that no major
mass reduction happened and FT-IR changes referred to formulation of a secon-
dary bond between the components.
Keywords: Clopidogrel bisulfate, Co-grinding, Crystallinity, FT-IR
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1 Introduction
In pharmaceutical processing, the amorphous form of com-
pounds frequently appears. It can be prepared deliberately
when the properties of a poorly water-soluble active pharma-
ceutical ingredient (API) need to be changed, or accidentally
when any of the ingredients convert into their amorphous form
during the formulation process [1]. In the deliberate case, the
amorphous form can be prepared in three ways: quench-cool-
ing of melts [2, 3], rapid solvent evaporation [4, 5], and grind-
ing [6–8]. Accidentally, the crystallinity of materials can de-
crease during many formulation processes, e.g., lyophilization
[9], spray-drying [10], tableting [11], nano-crystallization,
grinding etc. [12]. Generally, amorphous materials exhibit a
faster dissolution rate, but sometimes the other properties can
cause major problems in formulation: above the glass transition
temperature they become sticky, gummy, and viscous, thereby
making the formulation impossible. Mostly, the amorphous
form of the material is physically and chemically less stable
than the crystalline form [13, 14].
Grinding is a widely used process in pharmaceutical formu-
lation for particle size decreasing, micronization, and nano-
nization [15–19]. By increasing the specific area and making
spherical shapes, grinding can improve the dissolution rate of
poorly water-soluble drugs. Processes like grinding are often
accompanied by changes in the crystallinity of the material be-
cause of high energy input. It can cause polymorphic transfor-
mations, e.g., the amorphous form of a crystalline API may ap-
pear [20, 21]. This is especially true for co-grinding [22, 23],
when an appropriate excipient is used which is able to reduce
the free energy of the system and the energy demand of the
amorphization process. This can lead to a major decrease in
crystallinity [24].
Some materials show a higher tendency to exist in amor-
phous form. One of these materials which are named in litera-
ture as good glass formers, is CLP (methyl(+)-(S)-a-(2-chloro-
phenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate sulfate).
Several researchers prepared and analyzed the amorphous and
polymorphic forms of CLP [25–28]. The most popular and
easy way to turn CLP into its amorphous phase is solvent evap-
oration. For this method, any of its good organic solvents are
suitable, as demonstrated in a work formerly published by our
team. In that article, a physically stable amorphous form of
CLP was prepared and stabilized by Aerosil 200. The optimized
mass ratio of the components was 7:3 of CLP:Aerosil 200. In
this process, a generated hydrogen bond was also discovered
between silanol groups of Aerosil 200 and CLP molecules [29].
CLP is also appropriate for co-grinding because of its high
melting point (181.2 C) since it does not melt during milling.
Through the grinding process, the temperature of the system
had to be below the glass transition temperature (T)g
1) of the
CLP, which is 83 C [28], because below the Tg the free energy
and enthalpy of the system is much lower. Aerosil 200 was used
because of its amorphous properties, so it has neither any ther-
mal sign nor any peak on X-ray powder diffraction (XRPD)
diffractograms [30].
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The changes of crystallinity of a model powder mixture con-
taining CLP and Aerosil 200 during a long time co-grinding
process were determined. The interaction between CLP and
Aerosil 200 was studied to detect whether a H-bond forms also
by grinding. Finally, the changes of the crystallinity of the sys-
tem were quantified.
2 Materials and Methods
2.1 Materials
Pure polymorphic form II clopidogrel bisulfate (methyl(+)-(S)-
a-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-
acetate sulfate) was obtained from EGIS Nyrt., Budapest. Aero-
sil 200, a colloidal SiO2 with hydrophilic properties, was pur-
chased from Nippon Aerosil Co., Japan.
2.2 Co-Grinding
Co-grinding of the mixture of the two components was per-
formed in a planetary ball mill (Retsch PM 100, Retsch GmbH
& Co., Germany). The mass ratio of CLP and Aerosil 200 was
7:3, based on a previous work of our team. The maximum
grinding time was 240min. Samples were withdrawn for inves-
tigation after 15, 30, 45, 60, 90, 120, 150, 180, and 240min.
During the grinding procedure, the temperature was controlled
by an infrared thermometer. The temperature was not higher
than 60 C through milling.
2.3 Differential Scanning Calorimetry (DSC) and
Thermogravimetry (TG)
The DSC investigation was recorded with a Mettler-Toledo
DSC 821e instrument with an intercooler and the TG curve
was obtained by a TGA/DSC (Mettler-Toledo, Switzerland).
Sample portions of 4.5–5.5mg were crimped in aluminum pans
with two holes and examined in the temperature interval
25–200 C under an argon gas flow at 100–150mLmin–1. The
heating rate was 20 Cmin–1.
2.4 X-Ray Powder Diffraction (XRPD)
XRPD analysis was performed on a Bruker D8 Advance dif-
fractometer (Bruker AXS GmbH, Karlsruhe, Germany) system
with hot-humidity stage, with CuK kI radiation (k = 1.5406Å).
The samples were scanned at 40 kV and 30mA from 3 to 50
2h using a scanning speed of 0.1 s–1 and a step size of 0.010.
The relative humidity was 60%, the temperature range was 25,
80, and 95 C, and the heating rate was 20 Cmin–1. Crystallini-
ty determination was based on the total area below the curve
between 8 and 36 2h.
The quantification was based on the result of the XRPD
measurement. The crystallinity of the investigated material is
proportional to the area below the peak of the diffractogram.
Using this correlation, the crystallinity of each sample can be
quantified. The quantification is based on the total area below
the diffractograms between 8 and 36 2h after smoothing and
background removal.
For linearization of this function Avrami’s equation was ap-
plied:
X(t) = ln[–ln(1–DAf/DA0)] (1)
where Af is the netto area below the peaks and A0 is the netto
area below the peaks at 0min.
2.5 FT-IR Spectroscopy
FT-IR spectra were obtained with a Bio-Rad Digilab Division
FTS- 65A/896 FTIR spectrometer between 4000 and 400 cm–1,
at an optical resolution of 4 cm–1, operating Harrick’s Meridian
SplitPea single reflection, diamond, ATR accessory. Thermo
Scientific GRAMS/AI Suite software was used for spectral anal-
ysis.
3 Results and Discussion
3.1 DSC Determination
As thermal analysis techniques are widely used for character-
ization of amorphous forms [30, 31], the raw CLP, the Aerosil
200, and the prepared samples were investigated by DSC. The
curve of the raw CLP gave a characteristic sharp peak at
181.2 C, corresponding to the melting point of the material.
Any other changes were not observed on the curve, which
means that the CLP contained no moisture or any rest solvent.
The amorphous additive Aerosil 200 did not exhibit any ther-
mal signal, so it is practically amorphous and had no moisture
or any rest solvent either.
The curves of samples display that an endothermic peak of
the CLP’s melting point appears on each curve of the samples,
except for the last one at 240min (Fig. 1). The heights of the
peaks belonging to the melting point decreased with increasing
grinding time until they practically disappeared after 240min
of grinding. The peak of the physical mixture was similar to
the peak of the raw CLP, with a smaller area according to the
mass ratio. It indicates the decreasing crystallinity of the CLP
which was finally converted into the amorphous phase. The
peaks during grinding are slightly shifted to lower tempera-
tures. It was impossible to determine the exact peak areas be-
cause of the imprecise pre- and post-baseline fittings of the
melting peaks. The DSC method was not applicable for further
semi-quantitative determination.
3.2 X-Ray Diffraction
The XRPD process is an appropriate method to determine the
crystallinity of materials. The X-ray pattern of the raw CLP
exhibits characteristic high-intensity diffraction peaks, which
proves the crystalline nature of the unprocessed API. A com-
parison of the CLP determination with data from the Cam-
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proved that this API is of the polymorphic form II. The pattern
of Aerosil 200 does not show any peaks in the measured inter-
val, which means that the excipient is practically amorphous.
The typical peaks of the CLP emerge clearly on the diffracto-
grams of the ground products (Fig. 2). The intensities of these
peaks were lower than those of the peaks for the raw API corre-
sponding to the concentration of the materials in the samples.
The amorphous Aerosil 200 does not show any further reflection.
The intensities of these peaks are decreasing with longer grinding
time and practically disappear after co-grinding for 240min. The
diffractogram of the last sample displays the amorphous halo.
During the co-grinding process no other polymorphic form of
the CLP appeared because no shifting of the peaks or appear-
ance any new peak can be observed on the pattern.
Quantification of the crystallinity decrease was performed
according to Avrami’s equation and is displayed in Fig. 3. Ob-
viously, the decrease of the crystallinity changes sigmoidally
upon longer grinding time. The rise of the fitted trend line re-
fers to the speed coefficient of the formation of the amorphous
product. The regression line equation is:
y = –0.0233x + 1.619; R2 = 0.9935.
According to this phenomenon, the crystallinity of the prod-
ucts starts to decrease slowly. After a certain time is elapsed,
the decrease is getting faster, and at the end of the procedure
the curve of amorphization is flattening. This procedure can be
caused by an in-process formed secondary bond between the
API and the excipient because the formation of the bond is an
energy-intensive process.
3.3 TG and Hot-Humidity Stage XRPD
In the curves of the samples ground more than 120min an en-
dothermic peak can be observed at 80 C (Fig. 1). The area be-
low this peak is increasing and sharpening with longer grinding
time. To find the source of the peaks, the last sample, i.e.,
ground for 240min, was investigated by TG and hot-humidity
stage XRPD.The TG curve revealed that the product is thermo-
dynamically stable. Only 3.33% of mass decrease was detected
until the melting point of the CLP (Fig. 4). At 80 C, the deter-
mination did not show salient mass decrease which means that
the peak observed on the DSC pattern could not be ascribed to
dissolution or solvent evaporation. No major decrease was
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Figure 1. DSC curves of the samples were ground for 15, 30, 45,
60, 90, 120, 150, 180, and 240min. The endothermic peak of
CLP appears on each curve, and the areas below the peaks are
decreasing with the grinding time. After 120min of grinding an
emerging peak can be observed at 80 C.
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Figure 2. XRPD diffractograms of samples. The characteristic
peaks of CLP are decreasing with longer grinding time. The last
sample at 240min shows no peaks, so it is practically amor-
phous.
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found at 100 C which means that the sample was sufficiently
dry.
The last sample, ground for 240min, was determined by
XRPD using the hot-humidity chamber at room temperature of
25 C, at the temperature of the peak at 80 C, and at a hotter
temperature than the peak at 95 C. The diffractograms showed
an amorphous halo at all three times, so this peak does not refer
to any change of crystallinity (Fig. 5).
The outlined phenomenon could be the glass transition of
the amorphous complex since the Tg of the amorphous CLP is
around 83 C [28], although this signal change is more similar
to an endothermic peak and has not the shape of Tg, which is
just a baseline shift. This phenomenon is probably an emerging
secondary bond between the API and the additive. The de-
tected endothermic peak at 80 C displays the split of the bond.
At higher temperatures, the CLP-Aerosil 200 complex sepa-
rates and a solid dispersion of the two independent materials
arises.
3.4 FT-IR Spectroscopy
FT-IR spectroscopy is a suitable method for in-
vestigating interactions between pharmaceuti-
cal materials and polymers [33]. For FT-IR de-
termination, the attenuated total reflection
(ATR) method was chosen because sample
preparation such as particle size reduction or
KBr tableting is not required, which would ex-
pose the samples to further physical stress.
FT-IR results demonstrated that the grinding
process caused several small changes in the
spectra of the samples. One of the most spec-
tacular alterations was observed at 1752 cm–1,
which displays the mC=O valence vibration of
the CLP. These peaks of the samples ground
more than 120min expanded, shifted to lower
wavenumbers, and slightly increased in inten-
sity with longer grinding time (Fig. 6).
Another change was observed at 865 cm–1
where a band with high intensity starts to de-
crease after 120min of grinding, while a double
peak at 858 and 838 cm–1 fuses into one peak
www.cet-journal.com ª 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Chem. Eng. Technol. 2014, 37, No. 8, 1393–1398
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Figure 3. Crystallinity changes during grinding time. Function A shows the area below the curves decreasing with longer grinding time;
function B is the linearization of the first one.
a)
b)
Figure 4. DSC (A) and TG (B) analysis of sample ground for 240min. No major mass
decrease was detected at 80 or 100 C.
In
te
ns
ity
/c
ps
2 /°
Figure 5. Hot-XRPD diffractograms of sample ground for
240min at 25, 80, and 95 C. Each diffractogram shows the
amorphous halo. No changes happened in the crystallinity at
these temperatures.
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with a higher intensity (Fig. 7). These changes proportionally
follow the change at 1752 cm–1 which is also remarkable after
120min of grinding. The same phenomenon can be found
between 1200 and 1135 cm–1: the peak at 1188 cm–1 decreases,
while the peak at 1150 cm–1 slightly increase parallel after
120min of co-grinding.
After 120min of grinding a weak secon-
dary bond appears between the CLP and
the silanol groups of the CLP. This bond is
strong enough to keep the CLP in amor-
phous phase. Based on previous work [29],
this secondary bond can be considered as a
hydrogen-bond.
4 Conclusions
Results proved that major alterations can
be caused in the crystal structure of materi-
als during co-grinding. Already a few mi-
nutes of grinding can be enough to break
the long range order of the crystal, while
grinding for sufficiently long time can con-
vert the whole amount of the sample into
the amorphous phase. In this case, the sys-
tem containing CLP and the colloidal sili-
con dioxide Aerosil 200 started to lose its
crystallinity from the beginning of grinding
and needed 240min to become fully amor-
phous. DSC and XRPD measurements
demonstrated the course of decrease of
crystallinity. TG and FT-IR determinations
confirmed that no dissolution or solvent evaporation happened
during grinding. TG and hot-humidity stage XRPD proved that
the discovered peak at 80 C was neither moisture or rest sol-
vent nor change in crystallinity. FT-IR also determined a for-
matting secondary H-bond between CLP and Aerosil 200 mol-
ecules after 120min of grinding. The previous peak on the
DSC curve is a common signal of the split
of this hydrogen bond. This bond can sta-
bilize the molecularly disperse system in
the amorphous phase. Finally, quantifica-
tion of the phenomenon was performed by
XRPD diffractograms, and the speed coeffi-
cient was calculated using Avrami’s equa-
tion.
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Figure 6. FT-IR investigation of samples ground for 15 and 240min. The area below the
peak at 1750 cm–1 increased, and the peak shifted to lower wavenumbers.
Figure 7. Bands of Aerosil 200, CLP, and nine samples ground from 15 to 240min. The
area under peak at 865 cm–1 is decreasing after 120min of grinding, while the double
peak at 858 and 838 cm–1 fuses into one peak with a higher intensity.
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